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DIVERSITY’S PANDEMIC DISTRACTIONS
Jonathan Kahn, JD, PhD†
ABSTRACT
Pandemic diseases have a nasty history of racialization. COVID-19
is no exception. Beyond the obvious racist invocations of the “China
virus” or the “Wuhan Flu” are subtler racializing dynamics that are
often veiled in more benign motives but are nonetheless deeply
problematic. The racialization of COVID-19 proceeded along two
distinct trajectories each of which threatened to reinforce inaccurate
biologized conceptions of race while diverting attention from the social,
legal, and political forces historically structuring race-based health
disparities. First, early on as significant racial disparities in disease
incidence and mortality became evident, a frame of race-based genetic
difference came to the fore as a possible explanation.
Second, as vaccine development ramped up there came widespread
calls for racially “diversifying” clinical trials for the vaccines being
tested. The rationales for such diversification were varied but tended
to reinforce genetic frames of racial difference. Most common was the
assertion (without substantial evidence) that vaccines might work
differently in Black or Brown bodies and so racial diversity in trials was
imperative for reasons of safety and efficacy.
Derrick Bell cautioned 20 years ago that “the concept of diversity .
. . is a serious distraction in the ongoing efforts to achieve racial
justice.” (Derrick Bell, Diversity’s Distractions, 103 COLUM. L. REV.
1622, 1622 (2003).) This article explores the dynamics of how the
concept of “diversity” racialized responses to COVID-19 and considers
their broader implications for understanding and responding to racial
disparities in the face of pandemic emergencies and beyond. In the
short term, vaccine developers did a decent job of enrolling minorities
in their clinical trials and the vaccines have proven to have the same
safety and efficacy across races. In the long term, diversity in the
biomedical context of pandemic response not only distracts attention
from important structural causes of health injustice, but it also focuses
attention on the genetics of disparities in a manner that has the
potential to reinforce pernicious and false ideas of essential biological
difference among racial groups.
This article argues that an uncritical embrace of the idea of
diversity in analyzing and responding to emergent health crises has the
potential to distract us from considering deeper historical and structural
formations contributing to racial health disparities. It proceeds first by
exploring the dynamics through which initial responses to racial
†

Professor of Law and Biology, Northeastern University.
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disparities in COVID-19 became geneticized. It will then move on to
unpack the rationales for such racialization, examine their merits (or
lack thereof), and consider their implications for developing an
equitable response to pandemic emergencies. The next section will
examine the subsequent racialization of clinical trials for COVID-19
vaccines through the concept of “diversity.” It then moves on to
explore how the geneticization of COVID-19 racial disparities laid the
foundations for a similar geneticization of race in vaccine development.
It will argue that in failing to clearly distinguish social and biological
rationales for diversity, such framings, while generally well-intentioned,
are poorly supported and work in tandem with the geneticization of
racial disparities in COVID-19 morbidity and mortality to locate the
causes of disparities in the minds and bodies of minoritized populations;
again this distracts attention from the historical and structural forces
contributing to such disparities. The article concludes by recognizing
a certain intractability to the problems of using race in biomedical
research and practice, particularly in the context of public health
emergencies. It offers modest suggestions for improvement that could
have significant practical effects if taken to heart by researchers,
clinicians, and policy makers.
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INTRODUCTION
Pandemic diseases have a nasty history of racialization,1 and
COVID-19 is no exception. In 2020, as SARS-Cov-2 took hold and
spread through the United States, race quickly entered the narrative
framing of those seeking to identify, understand, and respond to the
virus.2 In some ways, the racialization of COVID-19 sadly and
predictably echoed older racist tropes of some foreign “other” being
responsible for the spread of disease.3 Invocations of the “China virus”
or the “Wuhan Flu” were common, particularly among President
Trump and other prominent Republicans, and thereby came to circulate
widely among the public.4 The tropes have persisted, giving rise to
increased anti-Asian violence throughout the United States.5
The racialization of COVID-19, however, has also proceeded along
two other distinct and perhaps more subtly problematic trajectories.
First, significant racial disparities in disease incidence and mortality
became evident early on. This was not particularly surprising given
long-standing disparities in underlying comorbidities and related
socioeconomic factors affecting exposure and response to the disease.
Nonetheless, as these disparities became evident, a frame of race-based
genetic differences emerged as a possible explanation. This is
problematic for many reasons, not least of which being the simple fact
that racial categories are variable and do not map onto any clearly
identifiable genetic groupings.6 To simply invoke the mantra “race is

1.

See, e.g., PRISCILLA WALD, CONTAGIOUS: CULTURES, CARRIERS, AND THE
OUTBREAK NARRATIVE (Duke Univ Press ed., 2008); Susan Craddock,
City of Plagues: Disease, Poverty, and Deviance in San Francisco, 56 J.
HIST. MED. 302, 302 (2001).

2.

See Keith Wailoo, Spectacles of Difference: The Racial Scripting of
Epidemic Disparities, 94 BULL. HIST. MED. 602, 602 (2020).

3.

Id. at 607-08.

4.

Tyler T. Reny & Matt A. Barreto, Xenophobia in the Time of a Pandemic:
Othering, Anti-Asian Attitudes, and COVID-19, TAYLOR & FRANCIS
ONLINE: POL., GROUPS, & IDENTITIES (May 28, 2020), https://
www.tandfonline.com/doi/full/10.1080/21565503.2020.1769693 [https://
perma.cc/B8DR-XDL6].

5.

See, e.g., Weiyi Cai, Audra D. S. Burch, & Jugal K. Patel, Swelling AntiAsian Violence: Who Is Being Attacked Where, N.Y. TIMES (Apr. 3,
2021), https://www.nytimes.com/interactive/2021/04/03/us/anti-asianattacks.html [https://perma.cc/72SJ-AVL9].

6.

The literature on this is voluminous. For a brief overview, see e.g.,
Jonathan Kahn et al., How Not To Talk About Race And Genetics,
BUZZFEEDNEWS (Mar. 30, 2018), https://www.buzzfeednews.com/
article/bfopinion/race-genetics-david-reich
[https://perma.cc/48SRQ7JY].
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socially constructed” is not enough.7 As anthropologist Alan Goodman
recently put it: “Race is real, but it’s not genetic.”8 There are, perhaps,
crude correlations that can be observed between racial groups and
certain biological characteristics.9 However, as Jonathan Marks has
observed, “to the extent that class differences may correlate with
biological differences, we can see that the reality of race is as a biocultural category – the intersection of natural human differences and
the culturally classificatory decisions about what kinds and what
amounts of differences matter.”10 In the specific realm of health
disparities, it is useful to consider epidemiologist Nancy Krieger’s
formulation that race-based health differences can be conceptualized as
“biologic expressions of race relations.”11 The genetic frame diverts
attention from the social, environmental or historical conditions that
account for COVID-19 disparities, focusing instead on the incorrectly
racialized genetic makeup of the affected groups to locate responsibility
at the molecular level. Such diversion is not merely incidental. It can
have a critical and wide-ranging impact upon how we marshal and
deploy resources in the short term; and in the long term it can impede
efforts to address the deeper structural issues that COVID-19
disparities have so powerfully brought to light.
Second, following readily upon the heels of this biologization of
racial disparities, as vaccine development ramped up there came
widespread calls for racially “diversifying” clinical trials for the vaccines
being tested. The rationales for such diversification were varied, but
tended to reinforce genetic frames of racial difference.12 Most common
7.

As sociologists, Michael Omi and Howard Winant have argued, race is
perhaps best understood as “an unstable and ‘decentered’ complex of
social meanings constantly being transformed by political struggle.”
MICHAEL OMI & HOWARD WINANT, RACIAL FORMATION IN THE UNITED
STATES: FROM THE 1960S TO THE 1990S 55 (2d ed. 1994).

8.

Alan Goodman, Race Is Real, But It’s Not Genetic, SAPIENS (Mar. 13,
2020), https://www.sapiens.org/biology/is-race-real/ [https://perma.cc/
8BBX-7ZY3].

9.

See, e.g., Vence L. Bonham, Eric D. Green, & Eliseo J. Pérez-Stable,
Examining How Race, Ethnicity, and Ancestry Data Are Used in
Biomedical Research, 320 JAMA 1513, 1533-34 (2018); Agustin Fuentes,
Race is Real, But Not in the Way Many People Think, PSYCHOL. TODAY:
BLOG (Apr. 9, 2012), https://www.psychologytoday.com/us/blog/
busting-myths-about-human-nature/20 1204/race-is-real-not-in-the-waymany-people-think [https://perma.cc/QQ68-TCG2].

10.

JONATHAN MARKS, IS SCIENCE RACIST? 58 (Polity Press ed., 2017).

11.

Nancy Krieger, If “Race” is the Answer, What is the Question?—On
“Race,” Racism, and Health: A Social Epidemiologist’s Perspective, SOC.
SCI. RES. COUNCIL (June 7, 2006), http://raceandgenomics.ssrc.org/
Krieger/#31 [https://perma.cc/3DM4-357R].

12.

See discussion infra Part II regarding “The Racialization of Vaccine
Trials.”
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was the assertion that vaccines might work differently in Black or
Brown bodies, and so racial diversity in trials was imperative for reasons
of safety and efficacy.13 The idea behind racial diversification was that
results from trials enrolling predominantly White subjects might not be
generalizable to other “populations.” Related to this was a more
politically-inflected concern that equitable distribution of vaccines
would more readily follow from diversified trials, especially because such
diversity would encourage trust among vaccine hesitant groups,
particularly African-Americans. Safety, Efficacy, Generalizability,
Equity, and Trust thus rapidly came to frame the drive toward
racializing vaccine development.14
Of course, it is appropriate, indeed, imperative, to be concerned
about the racially disparate impact of COVID-19 and also to work to
make sure that vaccines are safe, effective, and accessible to all. The
problem is not with these overarching concerns, but rather with their
being framed in geneticized conceptions of racial difference. Such
geneticization is enabled, indeed fueled, by the blurring, conflation, and
confusion of biological and social conceptions of diversity. While many
stories about race and COVID-19 have emerged and circulated during
the pandemic, the dominant narrative located responsibility for racial
disparities—both in disease impact and vaccine uptake—on the bodies
and minds of those suffering disproportionately from COVID-19. This
necessarily diverts attention from the historical and on-going structural
factors driving racial inequities in health, and has profound implications
both for biomedical understandings of race and for socio-political
approaches to addressing issues of racial justice in health.
In the 2003 Affirmative Action case of Grutter v. Bollinger, the
Supreme Court affirmed “diversity” as a constitutional rationale for
considering race as a factor in higher education admissions.15
Responding to the decision, Derrick Bell wrote a foundational article
titled “Diversity’s Distractions.” 16 While acknowledging the importance
of increasing minority enrollment colleges and graduate schools, Bell
cautioned that “the concept of diversity . . . is a serious distraction in
the ongoing efforts to achieve racial justice.” 17 For Bell, diversity itself
was not a bad thing; however, as a rationale for affirmative action it
“enable[d] courts and policymakers to avoid addressing directly the
barriers of race and class that adversely affect so many applicants.”18
Additionally, Bell argued, “[t]he tremendous attention directed at
13.

Id.

14.

Id.

15.

Grutter v. Bollinger, 539 U.S. 306, 343 (2003).

16.

Derrick Bell, Diversity’s Distractions, 103 COLUM. L. REV. 1622, 1622
(2003).

17.

Id.

18.

Id.
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diversity programs diverts concern and sources from the serious barriers
of poverty that exclude far more students from entering college than
are likely to gain admission under an affirmative action program.” 19
Similar dynamics have been at play in the invocation of diversity to
address disparities that have come to light during the COVID-19
pandemic. In the biomedical context of the pandemic response,
however, there is the added problem, not confronted by Bell, that
diversity not only distracts attention from important structural causes
of health injustice, it also focuses attention on genetics in a manner that
has the potential to reinforce pernicious and false ideas of essential
biological difference among racial groups.
This article argues that an uncritical embrace of the idea of
diversity in analyzing and responding to emergent public health crises
has the potential to distract us from considering deeper historical and
structural formations contributing to racial health disparities. First, in
Part I, it proceeds by exploring the dynamics through which initial
responses to racial disparities in COVID-19 became geneticized and will
then move on to unpack the rationales for such racialization, examine
their merits (or lack thereof), and consider their implications for
developing an equitable response to pandemic emergencies. Part II will
examine the subsequent racialization of clinical trials for COVID-19
vaccines through the concept of “diversity” and will then move on to
explore how the geneticization of COVID-19 racial disparities laid the
foundations for a similar geneticization of race in vaccine development.
In Part III, it will argue that in failing to clearly distinguish social and
biological rationales for diversity, such framings are poorly supported;
those framings also work in tandem with the geneticization of racial
disparities in COVID-19 morbidity and mortality to locate the causes
of disparities in the minds and bodies of minoritized populations. This
distracts attention from the historical and structural forces contributing
to such disparities. Finally, in Part IV, this article concludes by
recognizing a certain intractability to the problems of using race in
biomedical research and practice, particularly in the context of public
health emergencies. It offers modest suggestions for improvement that
could have significant practical effects if taken to heart by researchers,
clinicians, and policymakers.

I. GENETICIZING RACIAL IMPACT
When COVID-19 gained a foothold in the United States in early
2020, President Trump and other prominent Republican law makers
wasted little time in racializing the disease itself, repeatedly referring
to it as the “Wuhan Virus,” “Chinese Virus,” and “Kung Flu.” 20 Similar
recent examples of racialization of disease can be seen the responses to
19.

Id.

20.

Reny & Barretto, supra note 4.
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the 2013-2016 Ebola outbreak in Africa21 and in invocations of “African
AIDS” during the 1980s.22 This is hardly a new phenomenon. Historian
Keith Wailoo has explored how epidemics have long given rise to
“distinctive, recurring racial scripts about bodies and identities.”23 He
argues that the opening act of such scripts, from yellow fever epidemics
in the 18th century to cholera in the 19th century and influenza,
tuberculosis, and AIDS in the 20th, up to COVID-19 today, has created
a moment of “racial revelation” where “health experts and authorities
take note of Black people’s experiences, illnesses, or mortality as a
specific object of curiosity and social commentary.” 24 He argues that
“whether the moment of racial revelation focused on supposed Black
immunity or Black susceptibility, the revelation became material for an
ur-script . . . a plotline framed as a mystery of racial difference.” 25
President Trump declared COVID-19 to be a public health
emergency on January 31, 2020 and issued two national emergency
declarations on March 13.26 Before long, the racially disparate impact
of the virus became evident. On April 12, 2020, the COVID Tracking
Project started collecting race and ethnicity data from every state that
reported such data. On April 15, it launched the first iteration of the
COVID Racial Data Tracker using that dataset.27 Three days later,
Fordham law professor Catherine Powell coined the term “Color of
Covid” in an opinion piece for CNN, stating that people of color were
being hit particularly hard by the pandemic.28 The COVID Racial Data
Tracker and other subsequent studies would go on to document massive
racial disparities in morbidity and mortality from COVID-19 in the
Unites States. For example, one study found that as of June 17, 2020,
21.

Id. at 20.

22.

Lisa Betty, “Black Death”: Race and Representations of the Ebola
Epidemic and COVID-19 Pandemic, MEDIUM (May 30, 2020), https://
lbetty1.medium.com/black-death-race-and-representations-of-the-ebolaepidemic-and-covid-19-pandemic-479195d590
[https://perma.cc/XJ89D4KF].

23.

Wailoo, supra note 2, at 604.

24.

Id. at 605.

25.

Id. at 606.

26.

President Trump Declares State of Emergency for COVID-19, NAT’L
CONF. ST. LEG. (Mar. 25, 2020), https://www.ncsl.org/ncsl-indc/publications-and-resources/president-trump-declares-state-ofemergency-for-covid-19.aspx [https://perma.cc/27S3-BC9M].

27.

About the Racial Data Tracker, THE ATLANTIC: THE COVID TRACKING
PROJECT, https://covidtracking.com/race/about
[https://perma.cc/
K97D-ZYJP] (last visited May 21, 2021).

28.

Catherine Powell, Color of Covid: The Racial Justice Paradox of Our New
Stay-at-Home Economy, CNN (Apr. 18, 2020), https://www.cnn.com/
2020/04/10/opinions/covid-19-people-of-color-labor-market-disparitiespowell/index.html [https://perma.cc/3R3D-LJ2P].
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“[a]mong older adults, Blacks and Latinxs have death rates
approximately three and two times higher than Whites, respectively.”29
By September one report found that the infection rate for Hispanic
patients was over three times higher than the rate in White patients
(143 vs. 46 per 10,000), and the rate among Black patients was over
two times as high (107 per 10,000).30 Some targeted studies, such as one
in New York City, found that Blacks were five times more likely to
develop COVID-19 than Whites.31
As such racial differences became more evident, they also became
geneticized. Anthropologist Lance Gravlee flagged some of the crudest
forms of geneticizing COVID-19 racial disparities in a June 2020 blog
post for Scientific American. Gravlee noted that:
Louisiana Sen. Bill Cassidy, who was a medical doctor before
entering politics, claimed, without providing evidence, that
“genetic reasons,” among other factors, put African Americans at
risk of diabetes and, therefore, of serious complications from
COVID-19. Scientists writing in the Lancet, one of the world’s
leading medical journals, suggested—also without evidence—that
ethnic disparities in COVID-19 mortality may be partly
attributable to “genetic make-up” and speculated on a
“genomically determined response to viral pathogens.”
Epidemiologists writing in Health Affairs noted that “there may
be some unknown or unmeasured genetic or biological factors that
increase the severity of this illness for African Americans.”32

This last reference to “some unknown or unmeasured genetic or
biological factors” is particularly notable as it is a rhetorical move
repeatedly deployed to create a space for geneticizing disparities
without evidence. It is always available because one can never know all
of the causes of any given racial disparity. Much more reasonable and

29.

Marc A. Garcia et al., The Color of COVID-19: Structural Racism and
the Pandemic’s Disproportionate Impact on Older Racial and Ethnic
Minorities, GERONTOLOGICAL SOC’Y AM., 2020, at 1, 5.

30.

Lily Rubin-Miller et al., COVID-19 Racial Disparities in Testing,
Infection, Hospitalization, and Death: Analysis of Epic Patient Data,
KAISER FAM. FOUND. (Sept. 16, 2020), https://www.kff.org/coronaviruscovid-19/issue-brief/covid-19-racial-disparities-testing-infectionhospitalization-death-analysis-epic-patient-data/
[https://perma.cc/3CMV-EBR4].

31.

Charles DiMaggio et al., Black/African American Communities Are at
Highest Risk of COVID-19: Spatial Modeling of New York City ZIP CodeLevel Testing Results, 51 ANNALS EPIDEMIOLOGY 7, 9 (2020).

32.

Clarence Gravlee, Racism, Not Genetics, Explains Why Black Americans
Are Dying of COVID-19, SCI. AM.: VOICES (June 7, 2020), https://
blogs.scientificamerican.com/voices/racism-not-genetics-explains-whyblack-americans-are-dying-of-covid-19/ [https://perma.cc/TYS4-7VMC].
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responsible would be to assume a null hypothesis: racial disparities are
not due to genetics until proven otherwise.
Ironically, some of the earliest discussions of racialized genetic
difference involved spurious reports of Black immunity to the virus. On
March 10, Reuters reported about false claims circulating on social
media that “African Skin” resists the coronavirus.33 Around the same
time, a columnist with the Chicago Tribune noted similar rumors and
referenced a Twitter Live video posted by actor Idris Elba (who had
recently contracted the virus) pleading “with black people to stop
spreading the ‘scary’ rumor that they are immune,” calling it “the
quickest way to get more black people killed . . . around the world.”34
These examples do not address disparities per se, but they nonetheless
play into the moment of “racial revelation” where early on in the
pandemic race was becoming geneticized in relation to the virus. While
these early rumors of Black resistance to the virus were quickly
challenged, the search for genetic bases of COVID-19 susceptibility by
seemingly more reputable and prestigious biomedical researchers
rapidly became racialized in new and problematic ways.
Social media was not the only platform that began looking to
genetics to explain this observed phenomenon. In a September 2020
article published in the prestigious journal Nature, researchers claimed
to have identified a genetic risk locus for respiratory failure after
infection with SARS-CoV-2 that was inherited from Neanderthals and
present at much higher frequencies in people from South Asia and
Europe than Africa.35 Similarly, a published report from the direct-toconsumer genetics company, 23andMe found a “strong association
between blood type and COVID-19 diagnosis.”36 Specifically, it found
“that the O blood group was protective when compared to other blood

33.

See generally False Claim: African Skin Resists the Coronavirus, REUTERS
(Mar.
10,
2020),
https://www.reuters.com/article/uk-factcheckcoronavirus-ethnicity/false-claim-african-skin-resists-the-coronavirusidUSKBN20X27G [https://perma.cc/5RNV-ZGBU].

34.

Dahleen Glanton, Column: Let’s Stop the Spread – of the Myth Black
People Are Immune to the Coronavirus, CHI. TRIB. (Mar. 18, 2020),
https://www.chicagotribune.com/columns/dahleen-glanton/ct-dahleenglanton-coronavirus-black-immunity-myth-idris-elba-202003195auoqjzrmbcsphitbhpocth3qa-story.html [http://archive.today/mNBxI].

35.

Hugo Zeberg & Svante Pääbo, The Major Genetic Risk Factor for Severe
COVID-19 is Inherited From Neanderthals, 587 NATURE 610, 610-12
(2020).

36.

Janie F. Shelton et al., Trans-Ethnic Analysis Reveals Genetic and NonGenetic Associations with COVID-19 Susceptibility and Severity,
MEDRXIV

(Sept. 7, 2020), https://www.medrxiv.org/content/10.1101/
2020.09.04.20188318v1 [https://perma.cc/QM8Z-Y3J7].
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groups.” 37 O type blood is found the world over but is more common
in Africa than elsewhere.38
Subsequent research revealed a much more complex picture of
possible genetic bases for variable COVID-19 susceptibility. For
example, later studies cast into doubt the significance of ABO blood
group variation,39 and the same researchers who published the
Neanderthal study in September 2020 published a second study in
January 2021. In the second study, those researchers identified yet
another Neanderthal genetic risk locus, this time finding it to be
protective against severe COVID-19.40 Based on these studies, there
were apparently some genetic variants inherited from Neanderthals that
could make populations outside of Africa more susceptible to COVID19, and others than could make them less so. In any event, given that
only 2-3% of modern humans’ DNA derives from Neanderthals,41 it
seems likely that most genetic variations of relevance to COVID-19
susceptibility have nothing to do with our Neanderthal ancestry.
One of the factors contributing to early rumors of Black immunity
to contracting COVID-19 was the relatively low incidence rates in subSaharan African as COVID-19 spread in 2020. There were, however,
very clear non-genetic reasons explaining the much lower case-fatality
rate for Africa as compared to the rest of the world at that time. One
BBC report from October 2020 noted five reasons in particular.42 First,
“Quick Action:” this included the swift introduction of public health
measures such as avoiding handshakes, frequent hand-washing, social
distancing and wearing of face masks. Second, “Public Support:” for
example, in a survey conducted in 18 African countries, 85% of

37.

Id.

38.

See Jon Entine & Patrick Whittle, What’s ‘Race’ Got to Do with it? SubSaharan Africa Emerges as Coronavirus ‘Cold Spot’, Offering Clues to
Develop COVID-19 Vaccines, GENETIC LITERACY PROJECT (Mar. 31,
2020), https://geneticliteracyproject.org/2020/03/31/whats-race-got-todo-with-it-most-of-sub-saharan-africa-emerges-as-coronavirus-cold-spotwhich-may-offer-clues-to-finding-covid-19-vaccine/
[https://perma.cc/N7NJ-MM74].

39.

Erola Pairo-Castineira et al., Genetic Mechanisms of Critical Illness in
COVID-19, 591 NATURE 92, 96 (2021).

40.

Hugo Zeberg & Svante Pääbo, A Genomic Region Associated with
Protection Against Severe COVID-19 is Inherited from Neandertals,
PROC. NAT’L ACAD. SCI., 2021, at 1, 1-2, 4.

41.

See Nathaniel Sharping, How Much Neanderthal DNA Do Humans Have?,
DISCOVER MAG. (Apr. 28, 2020), https://www.discovermagazine.com/
planet-earth/how-much-neanderthal-dna-do-humans-have
[https://
perma.cc/X9BE-PVRP].

42.

Anne Soy, Coronavirus in Africa: Five reasons Why Covid-19 Has Been
Less Deadly Than Elsewhere, BBC (Oct. 8, 2020), https://www.bbc.com/
news/world-africa-54418613 [https://perma.cc/4MWG-QTRX].
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respondents said they wore masks in the previous week.43 Third, a
“Young Population” — and few old-age homes. Fourth, a “Favorable
Climate,” And fifth, “Good Community Health Systems:” particularly
those that were familiar with outbreaks of viruses such as Ebola and
methods of containing them.44
Many of these measures are similar to those taken by countries such
as New Zealand, which also had very low rates of COVID-19.45 But, of
course, no one was conducting any genetic studies of predominantly
European descended New Zealanders to try to understand why they
seemed so resistant to the ravages of the virus. When the unmarked
racial category of “White” was involved, it was assumed that political
and social interventions must have made the difference because other
“Western” (read “predominantly White”) countries without those
interventions still suffered from COVID-19.
The search for genes to explain disparities did not end with
Neanderthals and blood groups. As racial disparities became more
evident, studies of possible candidate genes to explain the difference
proliferated. Prominent among these were studies of genotypes encoding
for the Human Leukocyte Antigen (HLA) system,46 the angiotensinconverting enzyme-2 (ACE2) receptor,47 transmembrane serine protease

43.

Id.

44.

Id.

45.

Anna Jones, How Did New Zealand Become Covid-19 Free?, BBC (July
10, 2020), https://www.bbc.com/news/world-asia-53274085 [https://
perma.cc/HRQ8-F8T8].

46.

See generally Austin Nguyen et al., Human Leukocyte Antigen
Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus
2, J. VIROLOGY, 2020, at 1; Monojit Debnath et al., Genetic Gateways to
COVID-19 Infection: Implications for Risk, Severity, and Outcomes, 34
FASEB J. 8787 (2020); David J. Langton et al., The Influence of HLA
Genotype on Susceptibility to, and Severity of, COVID-19 Infection,
MEDRXIV (Jan. 4, 2021), https://www.medrxiv.org/content/10.1101/
2020.12.31.20249081v1.full [https://perma.cc/EEE8-Z9XX].

47.

See Debnath et al., supra note 46. See generally Yanan Cao et al.,
Comparative Genetic Analysis of the Novel Coronavirus (2019nCoV/SARS-CoV-2) Receptor ACE2 in Different Populations, CELL
DISCOVERY, 2020, at 1.
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2 (TMPRSS2) nasal gene expression,48 ion channel genetic variants,49
and prothrombin genetic mutations.50
HLA variants encode for the production of cell-surface proteins that
are responsible for the regulation of the immune system and are known
to vary significantly geographically across the globe.51 There are three
major histocompatibility complex (MHC) class 1 genes: HLA-A, HLAB, and HLA-C.52 These genes do not directly correlate with any racial
groups, but they (and their various alleles) do vary in their relative
frequencies in different populations across geographic space.53 Thus, for
example, one 2020 study identified global allele frequency distributions
by country for three representative alleles (HLA-A*02:02, HLAB*15:03, and HLA-C*12:03) thought likely to be protective for SARSCoV-2 and for three other three representative alleles (HLA-A*25:01,
HLA-B*46:01, and HLA-C*01:02) with the lowest predicted levels of
protection based on an in silico analysis.54 While all of the alleles were
found across the globe (i.e., none were race-specific), the study did
generally find a higher prevalence of the protective alleles in Africa and
a higher prevalence of less protective alleles in Europe.55 Whether or
not this in silico analysis actually plays out in vivo, it certainly cannot
be used to explain racial disparities because, like the ABO blood group
study and the first Neanderthal gene study, the results of this HLA
study would indicate a protective advantage on average for African
descended populations. Additionally, there is tremendous allelic
diversity in all major classes of the HLA system among populations
within Africa, so variable immune response is not simply of matter of
HLA diversity based on so-called continental populations.56
48.

See Supinda Bunyavanich, Chantal Grant, & Alfin Vicencio,
Racial/Ethnic Variation in Nasal Gene Expression of Transmembrane
Serine Protease 2 (TMPRSS2), 324 JAMA 1567, 1567 (2020). See
generally J.M. Carethers, Insights into Disparities Observed with COVID19, 289 J. INTERNAL MED. 463 (2020).

49.

See generally John R. Giudicessi et al., Genetic Susceptibility for COVID19-Associated Sudden Cardiac Death in African Americans, 17 HEART
RHYTHM 1487 (2020).

50.

See generally Rahul Chaudhary et al., Race-Related Disparities in
COVID-19 Thrombotic Outcomes: Beyond Social and Economic
Explanations, 29 ECLINICALMEDICINE, 2020, at 1.

51.

See Nguyen et al., supra note 46.

52.

Id. at 1.

53.

See Debnath et al., supra note 46, at 4.

54.

See Nguyen et al., supra note 46, at 6-7.

55.

Id. at 7.

56.

K. Cao et al., Differentiation Between African Populations is Evidenced
by the Diversity of Alleles and Haplotypes of HLA Class I Loci, 63 TISSUE
ANTIGENS 293, 293-94 (2004).
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One obvious molecular candidate for possible race-specific variable
response to COVID-19 was the ACE2 gene encoding the angiotensinconverting enzyme-2, which had been proved to be the receptor for the
SARS-CoV-1 and so was naturally looked to as a possible host receptor
for SARS-CoV-2.57 One study published in February 2020, just as
COVID-19 was taking hold, observed variable frequencies of certain
possible significant alleles across “East Asian,” “European,” “African,”
“South Asian,” and “Ad-Mixed American,” groups but also found “no
direct evidence supporting the existence of coronavirus S-protein
binding-resistant ACE2 mutants in different populations.”58 A later
study, published in May 2020, looked at both ACE2 and HLA loci
hypothesizing that “genetic variations within these gateways could be
key in influencing geographical discrepancies of COVID-19.”59 However,
the study concluded that “currently, there are no genetic data to
support ethnic/geographical variation of COVID-19 on global basis.”60
A study published in September continued to look at ACE2 and other
genes as possible contributors to COVID-19 disparities and similarly
acknowledged that “it is unknown how these genetic polymorphisms
contribute to the disparate mortality rates.”61 Nonetheless, the authors
of this study hypothesized that “genetic and biological risk for highly
relevant COVID-19 comorbid conditions may be critical to our ability
to understand and therefore address the observed health disparities in
the COVID-19 pandemic affecting US NHBs [non-hispanic blacks].”62
In pursuing this geneticized approach to disparities, the authors
tellingly wrote:
Population-specific risk in Black communities is clearly
multifactorial; however, recent research on the prevalence and
risk in the UK indicates that comorbidity and social determinants
of health only tell part of the story when it comes to accounting
for disease risk and mortality in vulnerable populations.
Naturally, biological risk likely fills the void, at least in some
part.63

In noting that “population-specific risk” is “multifactorial,” the
authors acknowledged social determinants of health but went on to
assert that those determinants tell “only part of the story.” The other
57.

Cao, supra note 47.

58.

Id.

59.

Debnath et al., supra note 46, at 8787.

60.

Id.

61.

Nicole Phillips et al., The Perfect Storm: COVID-19 Health Disparities in
US Blacks, 8 J. RACIAL & ETHNIC HEALTH DISPARITIES, 2020, at 1, 1.

62.

Id.

63.

Id.
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part of that story, it seems, must be biological; this implied despite the
fact that they present no hard evidence to support the claim.
Certainly, “biological risk” plays a role in COVID-19 prevalence,
but the authors conveniently blurred the distinction between biological
risk and race-specific biological risk and strangely reconfigured the
absence of evidence of such racialized risk into evidence of presence.
This is a common rhetorical move in biomedical studies seeking to
establish race-specific biological difference as an explanation for
disparities: authors often note that the social determinants they have
identified as contributing to disparities fail to explain the entirety of
the disparity, and they therefore assert that the residual disparities
must be caused by underlying (yet unidentified) race-specific biological
differences. 64
In this case, the authors posited “ancestral variations” in ACE2 as
a source of race-specific “biological risk.”65 They framed their discussion
of ACE2 with a reference to research from the UK which purported to
indicate that “social determinants only tell part of the story.”66 The
study was published in September 2020. Its reference for the UK claim
came from a news story from May 2020, which offered this striking
claim as its opening sentence:
People from Asian and black ethnic backgrounds are at increased
risk of dying from covid-19 and, contrary to speculation, this can
only be partly explained by comorbidity, deprivation, or other
risk factors, according to data from the largest study to date.67

Yet, the barely one-page-long news story from May 2020 also stated
in the fourth paragraph that:
[M]ore research was needed on whether some of the increased risk
[of dying from COVID-19] is from greater occupational exposure
with proportionally more people from black and minority ethnic
(BAME) backgrounds working in sectors such as healthcare or
transport. Research is also needed into a range of factors
throughout the disease pathway including access to testing,
treatment, and intensive care. 68

This assertion is hardly a convincing argument as to the likely
genetic basis for such disparities.
64.

For an extended discussion of this phenomenon, see JONATHAN KAHN,
RACE IN A BOTTLE: THE STORY OF BIDIL AND RACIALIZED MEDICINE IN A
POST-GENOMIC AGE 157-92 (2012).

65.

Phillips et al., supra note 61, at 4.

66.

Id.

67.

Jacqui Wise, Covid-19: Known Risk Factors Fail to Explain the Increased
Risk of Death Among People from Ethnic Minorities, BMJ, 2020, at 1, 1.

68.

Id.
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In October 2020, just one month after this article referenced
research in the UK to support the idea that race-specific “biological
risk” likely plays a role in disparities, the UK government issued its
first quarterly report on COVID-19 health inequalities.69 At that time,
the UK government report found that “existing research suggests that
biological factors such as genetics are unlikely to explain the inequalities
in ethnic groups from COVID-19.”70 As Reuters described, the report
found that “the increased risk to ethnic minorities from COVID-19 is
largely driven by factors such as living circumstances and profession
and not the genetics of different groups.”71
Nonetheless, another study published in March 2021, well after the
UK report, deployed now-common rhetorical frames to perpetuate the
idea that genes, not social determinants, might be responsible for
COVID-19 disparities.72 To support its observation that “both
biological and nonbiological factors seem to contribute to racial
disparities in COVID-19,” this article referenced a study purportedly
finding that African Americans “are likely more susceptible” due to a
polymorphism in the androgen receptor gene. 73 It also went on to
reference yet another study finding that “that African populations are
genetically predisposed to lower expression of ACE2 and TMPRSS2
and may therefore be less susceptible to the coronavirus.” 74
Putting aside the fact that these two studies (like the Neanderthal
gene studies) would seem to cancel each other out in terms of explaining
disparities, the authors’ strategic use of words such as “might,” “likely,”
and “seem to” is notable. On the one hand, such terminology is common
in scientific papers seeking to explore possible hypotheses. Here,
however, they are doing a different sort of work. For example, the
phrase “seem to” makes it appear that non-biological explanations for
disparities exist in the same speculative realm as biological
explanations. This is clearly not the case. The October UK report is
just one of many studies powerfully demonstrating the impact of “nonbiological” (i.e., social) factors causing race-based health disparities.
69.

See generally U.K. CABINET OFF., RACE DISPARITY UNIT, QUARTERLY
REPORT ON PROGRESS TO ADDRESS COVID-19 HEALTH INEQUALITIES
(Oct. 2020).

70.

Id. at 53.

71.

Socioeconomic Factors Drive COVID Risks for Minorities – UK
Government Report, REUTERS (Oct. 21, 2020), https://www.reuters.com/
article/us-health-coronavirus-britain-ethnicity/socioeconomic-factorsdrive-covid-risks-for-minorities-uk-government-report-idUSKBN2763CF
[https://perma.cc/RAJ7-4AWT].

72.

Geetanjali Saini et al., Disentangling the Coronavirus Disease 2019 Health
Disparities in African Americans: Biological, Environmental, and Social
Factors, OPEN FORUM INFECTIOUS DISEASES, 2021, at 1, 9.

73.

Id. (emphasis added).

74.

Id. (emphasis added).
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Only the studies of purported racial biological differences “seem to”
show some possible correlations between certain allele frequencies and
higher levels of morbidity or mortality. In the end, the authors deploy
these speculative terms not simply to further scientific exploration but
to create a space for geneticizing racial disparities.
The above-noted study referenced “African populations’”
differential expressions of ACE2 and TMPRSS2 and speculated that
“these data suggest that a genetic component might contribute to lower
numbers of reported COVID-19 cases in Africa.” 75 Yet, it also went on
to note that “it remains likely that non-genetic factors such as age and
comorbidities might play a more important role than host genetic
elements, especially in determining disease severity and outcome in
infected individuals.”76 In other words, even when identifying possible
genetic contributors to disparities, the authors of the cited study
carefully noted that the significance of genetic contributors likely paled
in comparison to non-genetic factors. Moreover, this study was of
variable “gene expression,” not of genetic variation itself.
As a different study of TMPRSS2 expression and COVID-19 stated,
“although this study suggests one factor that may partially contribute
to COVID-19 risk . . . many additional factors are likely, especially
because gene expression and race/ethnicity reflect multiple social,
environmental, and geographic factors. 77 In other words, study of the
impact of variable TMPRSS2 expression on COVID-19 disparities
cannot be separated from social and environmental factors. In the hands
of those arguing for strong genetic contributions to disparities, however,
such caveats tend to fall by the wayside. As Merlin, Chowkwanyun and
Adolph L. Reed Jr. cautioned in a May 2020 article, when such context
is lost, “data in a vacuum can give rise to biologic explanations for
racial health disparities.”78
Another study looking for possible genetic bases for COVID-19
racial disparities hypothesized that certain common ion-channelregulating genetic variants might be “contributing to the spike in
sudden deaths and racial health disparities observed in COVID-19
epicenters.” 79 These variants occurred at higher frequencies in
“individuals of African origin” and had been linked to “an increased
risk of ventricular arrhythmia (VA) and sudden cardiac death (SCD)
75.

Lourdes Ortiz-Fernández & Amr H. Sawalha, Genetic Variability in the
Expression of the SARS-CoV-2 Host Cell Entry Factors Across
Populations, 21 GENES & IMMUNITY 269, 271 (2020).

76.

Id.

77.

Bunyavanich et al., supra note 48, at 1568.

78.

Merlin Chowkwanyun & Adolph L. Reed, Jr., Racial Health Disparities
and Covid-19 – Caution and Context, 383 NEW ENG. J. MED. 201, 202
(2020).

79.

Giudicessi et al., supra note 49, at 1491.
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in African Americans across the age spectrum.”80 The authors of this
study also deployed the common rhetorical move of opening with an
acknowledgement that “this phenomenon is likely explained by the
convergence of multiple cultural and socioeconomic factors” before
moving on to hypothesize that “an underlying genetic susceptibility to
SARS-CoV-2 infection . . . could also contribute.” 81 Yet even on its
own terms, after creating this space for geneticizing racial disparities,
this study concluded that its hypothesis “remains to be proven” and,
strikingly, “may not even be testable.” 82
In contrast, the authors of a similar study looked at possible
relations between COVID-19 outcomes and purported genetic bases to
racial “thrombotic outcome disparities” (i.e. negative blood clotting
events) chose to subtitle their article “Beyond social and economic
explanations.”83 In this study, the authors hypothesized that
“differences in mortality and thromboembolic event occurrences in
COVID-19 may also be, in part, explained by important, but
comparatively unrecognized, race-related disparities in intrinsic
thrombogenicity.”84 The word “intrinsic” is critical here as it biologizes
the disparities of the affected racialized group. By way of comparison,
a systemic review of 68 studies exploring possible genetic contributions
to racial disparities in cardiovascular disease published in 2015 found
little evidence to support any purported genetic connection, concluding
that “most associations reported from genome-wide searches were small,
difficult to replicate, and in no consistent direction that favored one
racial group or another.”85
It has not been just the individual researchers foregrounding genetic
explanations of racial disparities, but major journals themselves. In the
wake of a major controversy surrounding a JAMA podcast that
effectively denied the existence of racism in the medical profession,
former New York City Health Commissioner Dr. Mary Bassett asserted
that “the biomedical literature just has not embraced racism as more
than a topic of conversation, and hasn’t seen it as a construct that
should help guide analytic work . . . But it’s not just JAMA — it’s all
of them.”86 With specific reference to COVID-19, Bassett lamented the

80.

Id. at 1490.
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Id. at 1487.
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Id. at 1491.
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Chaudhary et al., supra note 50.
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Id.
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Jay S. Kaufman et al., The Contribution of Genomic Research to
Explaining Racial Disparities in Cardiovascular Disease: A Systematic
Review, 187 AM. J. EPIDEMIOLOGY 464, 464 (2015).

86.

Apoorva Mandavilli, Medical Journals Blind to Racism as Health Crisis,
Critics Say, N.Y. TIMES (June 2, 2021), https://www.nytimes.com/

165

Health Matrix · Volume 32 · 2022
Diversity's Pandemic Distractions

telling example of JAMA rejecting her analysis of COVID-19 mortality
rates by race and age, while publishing another paper proposing that a
racial variation in a cellular receptor for the coronavirus might be an
explanation for the pandemic’s disproportionate toll on Black people.87
The above discussion is a representative sampling of the wide range
of articles published in major biomedical journals. Reviewing them is
important for several reasons. First, they set a narrative frame that
could have real impacts on understandings of and substantive responses
to the observed phenomenon of COVID-19 racial disparities. Second,
they play into and reinforce pre-existing dynamic of racialized care with
potential implications for triage and treatment in a time of public
health emergency. Third, they set the stage for racializing clinical trials
for vaccines in a manner that further reinforced the narrative that races
are genetically distinct groups, and these differences must play a role
in our response to COVID-19 (and other) health disparities.
A. Unpacking the Geneticization of Racial Disparities in COVID-19

Perhaps the most remarkable thing about the almost reflexive
search for genetic bases to COVID-19 health disparities was the
mountain of evidence that such disparities were profoundly and
overwhelmingly due to historical, social, environmental, legal, and
political (i.e., not genetic) factors. Even if some possible genetic
correlations to racial disparities were to be uncovered, the chances were
minimal that they would explain more than a tiny fraction of such
difference relative to the impact of non-genetic factors. This must have
been obvious to anyone with the slightest familiarity with the history
of racial disparities in the United States. As Lance Gravlee put it:
“[h]uman biology is more than the genome. Our environments,
experiences and exposures have profound impacts on how our bodies
develop, turning genetic potential into whole beings.”88 But if your idea
of looking at gene-environment interactions is considering how methyl
groups affect gene expression, perhaps you never develop a feel or
appreciation for considering the power forces beyond the genome to
shape health.
The non-genetic factors contributing to COVID-19 disparities were
myriad. Minoritized populations already bear a disproportionate burden
of underlying comorbidities that can place them at greater risk of higher
mortality from COVID-19. Moreover, not everyone is in an equal
position to manage their risk of encountering others with COVID-19.
As cardiologist Clyde Yancy notes, social distancing is a form of

2021/06/02/health/jama-racism-bauchner.html [https://perma.cc/SLY4265G].
87.

Id.

88.

Gravlee, supra note 32.
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privilege.89 Many of the conditions that have structured access to such
privilege along racial lines are the result of decades-long legal and
political actions, such as mortgage red-lining, employment
discrimination, and urban transportation policies.90 Such policies have
led to the reality that ethnic and racial minorities are more likely to
live in sub-standard crowded housing, be exposed to toxic
environmental pollutants, be forced to rely on public transportation,
and have reduced access to health care.91 They are also more likely to
work in settings that have been deemed “essential” such as healthcare
facilities, farms, factories, grocery stores, and public transportation,92
not to mention that these populations had, and have, higher rates of
incarceration in prisons where COVID-19 ran rampant.93
In their analysis of the legal underpinning of COVID-19 disparities,
Yearby and Mohapatra noted that “structural racism in employment
causes disparities in exposure; structural racism in housing causes
disparities in susceptibility; and structural racism in healthcare causes
disparities in treatment.”94 Moving from the structural to the
interpersonal, another study published in November 2020 found a
strong correlation between levels of implicit anti-Black bias among nonHispanic Whites and higher overall COVID-19 mortality rates and
larger Black-White incidence rate gaps. In that study, the authors
concluded that racism may not merely aggravate disparities, but may
actually be “harmful for everyone’s health.”95

89.

Clyde W. Yancy, COVID-19 and African Americans, 323 JAMA 1891,
1891 (2020).
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Ruqaiijah Yearby & Seema Mohapatra, Law, Structural Racism, and the
COVID-19 Pandemic, 7 J. L. & BIOSCIENCES 2, 4 (2020); Harriet A.
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Pandemic, NATURE (May 19, 2020), https://www.nature.com/
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As a September 2020 report from the National Academies of
Sciences, Engineering, and Medicine (NASEM) concluded:
”This disproportionate burden [of COVID-19 morbidity,
mortality, and transmission] largely reflects the impacts of
systemic racism and socioeconomic factors that are associated
with increased likelihood of acquiring the infection (e.g., frontline
jobs that do not allow social distancing, crowded living
conditions, lack of access to personal protective equipment,
inability to work from home) and of having more severe disease
when infected (as a result of a higher prevalence of comorbid
conditions or other factors).”96

All of these factors combined to offer up a decidedly non-genetic
menu of contributors to health disparities. Yet, as we saw above, the
search for genetic causes was widespread and on-going.
Not only were there many studies documenting the myriad nongenetic contributors to COVID-19 disparities, but there were also
studies explicitly concluding that genetics were not contributing to
COVID-19 disparities. In addition to the UK report mentioned above
finding that “biological factors such as genetics are unlikely to explain
the inequalities in ethnic groups from COVID-19,”97 NASEM similarly
declared in September 2020 that “currently there is little evidence that
this is biologically mediated, but rather reflects the impact of systemic
racism.”98 Further, longtime health and science reporter Gina Kolata
authored a December 2020 article in the New York Times with the
unequivocal title “‘Nothing to do with genes’: Racial gaps in pandemic
stem from social inequities, studies find.”99 One of the studies discussed
in Kolata’s article had recently been published in JAMA Network
Open.100 That study assessed racial disparities in hospitalization and
mortality in patients with COVID-19 in New York City hospitals. It
96.

NAT’L ACAD. SCI., ENG’G, & MED., FRAMEWORK
ALLOCATION OF COVID-19 VACCINE 9 (2020).
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U.K. CABINET OFF., RACE DISPARITY UNIT, supra note 69.
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MED. (Sept. 1, 2020), https://www.nationalacademies.org/news/2020/
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[https://perma.cc/6F8EPADP].
99.
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[https://perma.cc/68CF-88XM].
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Hospitalization and Mortality in Patients with COVID-19 in New York
City, JAMA NETWORK OPEN, 2020, at 1, 1.
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found that “[a]lthough Black patients were more likely than White
patients to test positive for COVID-19, after hospitalization they had
lower mortality, suggesting that neighborhood characteristics may
explain the disproportionately higher out-of-hospital COVID-19
mortality among Black individuals.” 101 Ultimately, this led to the
conclusion that “existing structural determinants pervasive in Black
and Hispanic communities may explain the disproportionately higher
out-of-hospital deaths due to COVID-19 infections in these
populations.”102 In commenting on the study for the Times story, its
lead author Dr. Gbenga Ogedegbe noted that “‘[w]e hear this all the
time — ‘Blacks are more susceptible’ . . . It is all about the exposure.
It is all about where people live. It has nothing to do with genes.’”103
A similar study of hospitalization and mortality in Louisiana,
published in June 2020 in the New England Journal of Medicine,
likewise found that “Black race was not associated with higher inhospital mortality than white race.” 104 That is, once they were
admitted, Black patients fared no worse than White patients.
Therefore, the study concluded, differences in clinical presentation and
mortality likely reflected social factors such as risk of community
exposure or “longer wait to access care.”105 In a larger study of 92
hospitals across 12 states, Yehia and colleagues found that “there was
no statistically significant difference in all-cause, in-hospital mortality
between White and Black patients after adjusting for other factors.”106
This study again indicated that once Black patients actually obtained
access to comparable care, the disparities in mortality disappeared.
Now contrast these studies with those discussed earlier that looked,
for example, “beyond social and economic explanations”107 for genetic
bases to explain COVID-19 disparities. The former are based on
empirical observations of existing conditions informed by historical
understandings of the social structures shaping those conditions. The
latter tend to be abstract hypotheses of possible genetic pathways that
might involve differing certain alleles that occur at different frequencies
in certain socially identified racial groups. Such studies almost always
involve trying to explain conditions that disproportionately impact
101. Id.
102. Id. at 2.
103. Kolata, supra note 99.
104. Eboni G. Price-Haywood et al., Hospitalization and Mortality among
Black Patients and White Patients with Covid-19, 382 NEW ENG. J. MED.
2534, 2534 (2020).
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US Hospitals, JAMA NETWORK OPEN, 2020, at 1, 6.
107. Chaudhary et al., supra note 50.
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social groups that have experienced a history of social dispossession and
injustice.
On the one hand, it is quite reasonable to want to explore how
genes contribute to the spread and severity of COVID-19. Such analysis
was central to the development of the mRNA vaccines by Pfizer and
Moderna.108 However, looking for a genetic explanation of the structure
and functioning of SARS-COV-2 is not the same thing as using genes
to explain racial disparities in morbidity and mortality in those
suffering from COVID-19. Epidemiologist Jon Zelner at the University
of Michigan lead another of the studies discussed in the Kolata article.109
He asserted that the toll on Black and Hispanic Americans “could easily
have been ameliorated in advance of the pandemic by a less threadbare
and cruel approach to social welfare and health care in the U.S.” 110
Trying to find race-specific genetic differences to explain such
disparities not only has little scientific basis, it also diverts attention
exactly from these sorts of historical and social inequities that pre-dated
the pandemic and structured its racialized impact.
Misconceiving the relationship between race and biological
difference can also negatively impact medical treatment. Racism in
medical treatment and research has a long and sordid history in this
country.111 In 1966, Martin Luther King Jr. is said to have declared that
“[o]f all the forms of inequality, injustice in health care is the most
shocking and inhumane.”112 Incidents of racial bias in access to and
delivery of health care have been glaringly evident at least since the
publication in 2002 of Unequal Treatment: Confronting Racial and
Ethnic Disparities in Health Care.113 This major study, sponsored by
the Institute of Medicine, considered racial inequities in quality of care

108. U.S. FOOD & DRUG ADMIN., FDA BRIEFING DOCUMENT PFIZER-BIONTECH
COVID-19 VACCINE 7 (Dec. 10, 2020); Tal Zaks, Chief Medical Officer at
ModernaTX, Presentation to FDA, Emergency Use Authorization (EUA)
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within multiple facets of the health infrastructure.114 Unequal
Treatment focused on social factors but following the completion of the
Human Genome Project in 2003, genetic studies of racial disparities
seemed to proliferate.115
As COVID-19 was ravaging the country in the summer of 2020,
Vyas et al. published a major study in the New England Journal of
Medicine documenting the problems created by the “subtle insertion of
race into medicine [through] diagnostic algorithms and practice
guidelines that adjust or ‘correct’ their outputs on the basis of a
patient’s race or ethnicity.”116 The authors stated:
Physicians use these algorithms to individualize risk assessment
and guide clinical decisions. By embedding race into the basic
data and decisions of health care, these algorithms propagate
race-based medicine. Many of these race-adjusted algorithms
guide decisions in ways that may direct more attention or
resources to white patients than to members of racial and ethnic
minorities. 117

Such disparate allocation of attention and resources might be
justified if there were a true genetic basis to the racial algorithms, but
the Vyas study found that developers of such algorithms often had
either no clearly articulated rationale for using race as they did, or used
rationales based on faulty or outdated data. 118
This is problematic both for immediate concerns of quality of care
and also because, as the authors noted:
Most race corrections implicitly, if not explicitly, operate on the
assumption that genetic difference tracks reliably with race. If the
empirical differences seen between racial groups were actually due
to genetic differences, then race adjustment might be justified:
different coefficients for different bodies.
Such situations, however, are exceedingly unlikely. Studies of the
genetic structure of human populations continue to find more
variation within racial groups than between them. 119

114. Id.
115. See Lundy Braun et al., Racial Categories in Medical Practice: How Useful
Are They?, 4 PLOS MED. 1423, 1424 (2007); KAHN, supra note 64, at 293.
116. Darshali A. Vyas, Leo G. Eisenstein, & David S. Jones, Hidden in Plain

Sight – Reconsidering the Use of Race Correction in Clinical Algorithms,
383 NEW ENG. J. MED. 874, 874 (2020).
117. Id.
118. Id. at 879.
119. Id.
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This study looked at race-adjusted algorithms in such areas as
cardiology, nephrology, and obstetrics. It concluded that “by
embedding race into the basic data and decisions of health care, these
algorithms propagate race-based medicine. Many of these race-adjusted
algorithms guide decisions in ways that may direct more attention or
resources to white patients than to members of racial and ethnic
minorities.”120 This study was conducted largely before COVID-19 had
taken hold in the United States, but it speaks directly to how the
biologization of racial difference can affect access to and delivery of
care.
As the nature of COVID-19 became better understood, doctors
began looking to measure levels of oxygen in the blood using devices
known as pulse oximeters to diagnose hypoxemia, or low blood oxygen,
as indicative of the presence and severity of the disease. A pulse
oximeter is a clamp-like device that clips onto a finger. As a Michigan
study published in the New England Journal of Medicine in December
2020 noted, “[o]xygen is among the most frequently administered
medical therapies, with a level that is commonly adjusted according to
the reading on a pulse oximeter that measures patients’ oxygen
saturation.”121 Yet this study of two large cohorts determined that
Black patients had nearly three times the frequency of occult
hypoxemia that was not detected by pulse oximetry as White
patients. Given the widespread use of pulse oximetry for medical
decision making, these findings have some major implications,
especially during the current coronavirus disease 2019 (Covid-19)
pandemic. Our results suggest that reliance on pulse oximetry to
triage patients and adjust supplemental oxygen levels may place
Black patients at increased risk for hypoxemia.122

The reason for this particular technologically mediated disparity is
fairly simple. Pulse oximeters work by sending two types of red light
through the finger from one arm of the clamp which is then picked up
by a sensor of the other side to detect the color of your blood. The
redder the blood, the more highly oxygenated it is. But pulse oximeters
were developed using algorithms calibrated to detect oxygen levels in
lighter skinned people; so they often mis-read blood levels of darker
skinned people. This has nothing to do with the genetics of blood
oxygen levels, it has to do with using a white norm to develop
diagnostics.
Following the publication of the New England Journal of Medicine
study, Senators Ron Wyden, Cory Booker, and Elizabeth Warren wrote
120. Id. at 874.
121. Michael W. Sjoding et al., Racial Bias in Pulse Oximetry Measurement,
383 NEW ENG. J. MED. 2477, 2477 (2020).
122. Id. at 2478.
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to the acting director of the FDA requesting it “conduct a review of the
interaction between a patient’s skin color and the accuracy of pulse
oximetry measurements.”123 The following month, the FDA issued a
public warning about the devices, acknowledging they had limitations
but pointedly not using the word “race.” Instead, the FDA alert
cautioned that “a recent report . . . suggests that the devices may be
less accurate in people with dark skin pigmentation.”124 On the one
hand, this alert appropriately decoupled dark skin pigmentation (a
biological attribute) from race (a social attribute). On the other hand,
the original report explicitly mentioned race in part because it noted
that the inaccuracies in pulse oximeter readings could have racially
disproportionate impacts that might aggravate already existing health
disparities. This is one of the great tensions in using race in medicine—
sometimes taking race out of the picture obscures the impact of racism.
A February 2021 Comment published in The Lancet Respiratory
Medicine similarly asked: “Could routine race-adjustment of
spirometers exacerbate racial disparities in COVID-19 recovery?”125
Spirometers are devices that originated in the 19th century, used to
measure lung function. As Lundy Braun has shown in her masterful
study of the development and application of spirometry, the use of the
device has long been plagued by the use of highly problematic and
inaccurate “race-corrections” that often lead to the misdiagnosis of
Black patients.126 The authors of the 2021 Comment cautioned that
“these race adjustments could potentially cause clinicians to miss
important diagnoses” in Black COVID-19 patients and “influence
treatment plans” to their detriment. 127
Biologized racial difference in relation to COVID-19 has also been
invoked under very different circumstances, for example, in trying to
obtain compassionate release from prison. In such instances, courts have
embraced the idea of race as social rather than genetic construct in
order to deny those compassionate release requests. In one federal case,
a prisoner seeking COVID-19-related compassionate release from prison
cited a number of physiological conditions which he alleged placed him
at higher risk for severe COVID-19. Among them: simply that he was
123. Letter from Elizabeth Warren, Ron Wyden, & Cory A. Booker, Senators,
to Dr. Janet Woodcock, Acting Comm’r, U.S. Food & Drug Admin. (Jan.
25, 2021) (on file with the U.S. Senate).
124. U.S. FOOD & DRUG ADMIN., SAFETY COMMUNICATION ON PULSE OXIMETER
ACCURACY AND LIMITATIONS (2021).
125. Meredith A. Anderson et al., Could Routine Race-Adjustment of
Spirometers Exacerbate Racial Disparities in COVID-19 Recovery?, 9
LANCET RESPIRATORY MED. 124, 124 (2021).
126. LUNDY BRAUN, BREATHING RACE INTO THE MACHINE: THE SURPRISING
CAREER OF THE SPIROMETER FROM PLANTATION TO GENETICS 204-05
(2014).
127. Anderson et al., supra note 125.
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an “African-American male” and that “the virus has hit the AfricanAmerican community particularly hard and is killing men at a higher
rate than women.”128 The court refused his release plea, noting that
“[w]hile some have suggested that genetic factors might explain these
differences, defendant concedes that the reasons remain unknown.” 129
Similarly, in the case of United States v. Alexander, the court denied
the defendant prisoner’s application for compassionate release, stating
that:
[I]t is not clear that being African-American increases Defendant’s
risk of complications from the COVID-19, in the same manner as
one’s underlying medical conditions. Indeed, although African
Americans are overrepresented in data regarding COVID-19
hospitalizations and deaths in America as a whole, this
overrepresentation may result from other systemic economic and
social issues affecting the African American community, including
access to health care, higher prevalence of underlying conditions,
and lack of access to health insurance.130

In response to a similar claim from a prisoner in Colorado, federal
district court Judge Robert Blackburn cited anthropologist Lance
Gravlee’s Scientific American post to support his contention that
“[a]lthough some researchers suggest there also may be a biological
component to African Americans’ observed susceptibility to the
disease . . . that idea is neither proven nor uncontested . . . . It thus is
entirely speculative whether Mr. Billings’s race, in and of itself,
increases his risks of contracting the virus or experiencing a more severe
course of the virus. This consideration therefore cannot be considered
compelling.”131
In light of the legal underpinnings to COVID-19 disparities
identified by Yearby and Mohapatra,132 the irony of federal courts
embracing the idea that race is not genetic is palpable. While these
courts certainly get the science right, this position stands in marked
contrast to the ways in which representatives from other federal
agencies, pharmaceutical corporations, and academic research centers
discussed [referred to] race and biological difference in relation to
COVID-19 during the same period of time. Specifically, those
representatives, agencies, and corporations made repeated and
128. United States v. Johnson, No. 17-CR-162, 2020 U.S. Dist. WL 2770266,
at *5 (E.D. Wis. May 28, 2020).
129. Id. at *1, *5.
130. United States v. Alexander, No. CV 19-32, 2020 U.S. Dist. WL 2507778,
at *4 (D.N.J. May 15, 2020).
131. United States v. Billings, No.19-CR-00099-REB, U.S. Dist. WL 4705285,
at *3 n. 5 (D. Colo. Aug. 13, 2020) (citing Gravlee, supra note 32).
132. Yearby & Mohapatra, supra note 91.
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widespread calls to “diversify” clinical trials for COVID-19 vaccines by
enrolling more Black bodies as subjects. One might well wonder why it
is that some agents of the federal government were so willing to embrace
ideas about the social construction of race when it served to keep Black
bodies in detention while under different circumstances other agents of
the federal government were so ready to invoke biological racial
difference as grounds for enrolling Black bodies in clinical trials. Such
divergence points up the importance of examining the work that a given
conceptualization of race is doing is different contexts, and in whose
interests such conceptualizations are being deployed. This is the subject
of the next section of this article.

II. THE RACIALIZATION OF VACCINE TRIALS
The broad discussions of biological difference framing COVID-19
disparities created a powerful rationale for racializing emergent vaccine
trials by calling for inclusion of “diverse” bodies as a scientific
imperative. At the same time that discourses of biological difference
were being used by some to explain disparities, others were using
biological difference as a purported basis for addressing disparities. As
sociologist Steven Epstein showed over a decade ago in his masterful
book, Inclusion: The Politics of Difference in Medical Research,
diversifying the racial composition of clinical trials has been a growing
concern of researchers and the federal government since the 1980s.133 A
key transitional moment in this story was the passage of the 1993 NIH
Revitalization Act, which required that women and members of
“minority groups” be included as research subjects in NIH-funded
studies unless a valid reason for non-inclusion was articulated. The Act
also established an Office of Research on Minority Health within the
NIH.134
Despite the passage of the Act, some of those working on health
disparities expressed discomfort at the implicit geneticization of racial
differences encompassed in such calls for inclusion. Otis Brawley, then
director of NCI’s Office of Special Populations Research, worried that
implementation of the NIH Revitalization Act Guidelines “may
eventually do more harm than good for the minority populations that
it hopes to benefit. The legislation’s emphasis on potential racial
differences fosters the racism that its creators want to abrogate by
establishing government-sponsored research on the basis of the belief
that there are significant biological differences among the races.”135

133. STEVEN EPSTEIN, INCLUSION: THE POLITICS
RESEARCH 1-2 (2008).
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134. Id. at 82.
135. Otis W. Brawley, Response to “Inclusion of Women and Minorities in
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Moreover, Brawley opined, it might “distract from truly important
health care issues[] . . . [by] encourag[ing] scientists to waste time and
resources looking for minute, insignificant biological differences and to
ignore social and environmental influences.” 136
Yet since 1994, diversity in clinical trials has been a mantra of the
industry even as racial disparities have persisted and in some cases
deepened. In 1997 Congress passed the FDA Modernization Act, which
called upon pharmaceutical companies to include racial data in their
new drug approval submissions.137 The FDA itself followed up with
official guidance papers in 1999,138 2005,139 and 2016,140 each of which
encouraged and provided direction for the collection of race-specific
data in the drug development and approval process.
This is not to say that such calls for diversity in clinical trials were
nefarious or wholly without merit. Certainly, racial inclusion, when
understood as related to variable social, environmental, and historical
conditions along with differential rates of comorbidities, can be very
relevant for clinical trials and a potential way to address issues of racial
equity. However, it is very difficult, though not impossible, to maintain
the use of racial categories as social variables once introduced into
biomedical contexts. This is especially true where the researchers
involved are generally not trained to understand or appreciate the
complexities of race as a bio-cultural construct – that is, a social
construct with very real biological implications for individuals whose
bodies are being racialized. The general foundations for racializing
COVID-19 clinical trials were thus broad and deep, but the proximate
context and frame for racializing specific vaccine trials in 2020 was
clearly conditioned by the racialization of the disease itself.
Calls for racial inclusion and diversity in clinical trials for COVID19 vaccines came early and persistently from a wide variety of sources,
ranging from industry and government to media, civil rights groups,
and the biomedical community itself. As early as April 2020, a group
of sixteen U.S. Democratic Senators sent an open letter to the CEOs of
major pharmaceutical corporations requesting that “that any vaccine
of NIH Clinical Trialists,” 16 CONTROLLED CLINICAL TRIALS 293, 293
(1995).
136. Id.
137. Food and Drug Administration Modernization Act of 1997, Pub. L. No.
105-115, 111 Stat. 2296 (1997) (codified as amended in scattered sections
of 21 U.S.C.).
138. Guidance for Industry on Population Pharmacokinetics, 64 Fed. Reg. 6663
(Feb. 10, 1999).
139. Guidance for Industry on the Collection of Race and Ethnicity Data in
Clinical Trials, 70 Fed. Reg. 54,946 (Sept. 19, 2005).
140. U.S. FOOD & DRUG ADMIN., COLLECTION OF RACE AND ETHNICITY DATA
IN CLINICAL TRIALS: GUIDANCE FOR INDUSTRY AND FOOD AND DRUG
ADMINISTRATION STAFF (2016).
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or therapeutic drug trials related to COVID-19 include women,
minorities, and LGBTQ+ persons.”141 The letter noted various social
factors contributing to already-observed racial disparities in COVID-19
morbidity and mortality and noted that “alarming research shows that
although ‘African Americans represent 12% of the United States
population, they make up only 5% of all clinical trial participants. Only
1% of clinical trial participants were Hispanic, though they comprise
16% of the national population.’”142
In July 2020, NIH Director Francis Collins and CDC Director
Robert Redfield appeared before a Senate subcommittee with other top
government scientists, they emphasized the importance of diversifying
COVID-19 vaccine trials. Redfield insisted that “‘[t]he last thing we
want is to be trying to recommend who gets the vaccine and we don’t
have any data on how the vaccine works in the population’ that needs
it.”143 Similarly, in August, Dr. Anthony Fauci, director of the National
Institute of Allergy and Infectious Diseases, expressed his desire “to see
minorities enrolled in coronavirus vaccine trials at levels at least double
their percentages in the population, because COVID-19 has hit those
groups especially hard.”144
By June 2020, the FDA had already issued a “Guidance for
Industry on the Development and Licensure for Vaccines to Prevent
COVID-19,” which “encourage[d] the inclusion of diverse populations
in all phases of vaccine clinical development.”145 In November, it
followed up with another Guidance, this time specifically on
“Enhancing the Diversity of Clinical Trial Populations” wherein it
elaborated on issues of eligibility criteria, enrollment practices and trial
design and noted that the FDA had been steadily working to diversify
clinical trials over the past few decades.146
Prominent academic and non-profit organizations such as the
Henry Ford Health System and the Kaiser Family Foundation similarly
emphasized the importance of racially diversifying COVID-19 vaccine
141. Letter from Robert Menendez et al., Senators, to David A. Ricks, Chief
Exec. Officer, Eli Lily & Co. (Apr. 20, 2020) (on file with the U.S. Senate).
142. Id.
143. Mary Chris Jaklevic, Researchers Strive to Recruit Hard-Hit Minorities
Into COVID-19 Vaccine Trials, 324 JAMA 826, 827 (2020).
144. Elizabeth Cohen, Moderna Increases Minority Numbers in Its Vaccine
Trial, But Still Not Meeting Fauci’s Goal, CNN (Aug. 29, 2020),
https://www.cnn.com/2020/08/29/health/moderna-coronavirus-vaccineminorities-goal/index.html [https://perma.cc/V2TX-UQFC].
145. U.S. FOOD & DRUG ADMIN., DEVELOPMENT AND LICENSURE OF VACCINES
TO PREVENT COVID-19: GUIDANCE FOR INDUSTRY (2020) [hereinafter
GUIDANCE FOR INDUSTRY].
146. Enhancing the Diversity of Clinical Trial Populations – Eligibility,
Criteria, Enrollment Practices, and Industry, 85 Fed. Reg. 71,654 (Nov.
10, 2020).
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trials. They released statements purporting to explain “Why [] Diversity
[Is] So Important In Vaccine Trials[]”147 and declared that “[e]nsuring
racial and ethnic diversity in clinical trials for development of COVID19 vaccines is particularly important[.]”148 Especially resonant were the
calls from prominent Black leaders in the medical community, such as
the National Medical Association (the largest and oldest national
organization representing African-American physicians) and leaders at
Historically Black Colleges and Universities (HBCUs). In June, the
National Medical Association and the Alliance of Multicultural
Physicians urged Congress and the FDA “to make diversity in clinical
trials a greater priority.”149 Similarly, the Presidents of Dillard and
Xavier Universities issued a joint statement in September 2020,
declaring that “[i]t is of the utmost importance that a significant
number of black and brown subjects participate” in COVID-19 vaccine
trials.150 That same month, representatives of four historically Black
medical schools (Meharry Medical College, Howard University,
Morehouse School of Medicine, and Charles Drew University of
Medicine and Science) stated their commitment “to the inclusion of
Black, Indigenous and people of color (BIPOC) as we engage in research
initiatives focused on the novel coronavirus, SARS CoV-2.”151
Popular media reported widely on the calls for clinical trial
diversity. In August, National Public Radio aired an interview with
Renee Mahaffey Harris, president of the Center for Closing the Health
Gap, which was titled “More People of Color Needed in COVID-19
Vaccine Trials.”152 That same month, STAT News published a story
147. Why Is Diversity So Important In Vaccine Trials?, HENRY FORD HEALTH
SYSTEM (Nov. 24, 2020), https://www.henryford.com/blog/2020/11/
diversity-in-vaccine-trials [https://perma.cc/F3BD-SWZT].
148. Samantha Artiga et al., Racial Diversity within COVID-19 Vaccine
Clinical Trials: Key Questions and Answers, KAISER FAM. FOUND. (Jan.
26, 2021), https://www.kff.org/racial-equity-and-health-policy/issuebrief/racial-diversity-within-covid-19-vaccine-clinical-trials-keyquestions-and-answers/ [https://perma.cc/FYY3-VTHC].
149. COVID-19 Treatments Must Work for Communities of Color, NAT’L
MED. ASS’N (June 11, 2020), https://www.nmanet.org/news/512553/
COVID-19-Treatments-Must-Work-for-Communities-of-Color.htm
[https://perma.cc/MV3S-326B].
150. Walter M. Kimbrough & C. Reynold Verret, A Message From the
Presidents of Dillard and Xavier, DILLARD UNIV. (Sept. 2, 2020),
https://dillard.edu/communications/news/xavier-dillard-vaccinetrials.php [https://perma.cc/GP66-G7YU].
151. Wayne A. I. Frederick et al., Joint Statement on the Integrity of Vaccine
Trials and the Inclusion of Black, Indigenous and People of Color, HOW.
NEWSROOM (Sept. 17, 2020), https://newsroom.howard.edu/newsroom/
article/13236/joint-statement-integrity-vacc [https://perma.cc/MM7CZPN6].
152. More People of Color Needed In COVID-19 Vaccine Trials, NAT’L PUB.
RADIO (Aug. 23, 2020), https://www.npr.org/2020/08/23/905181731/
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noting “Covid-19 clinical trials are failing to enroll diverse populations,
despite awareness efforts.”153 In June, NBC National News ran a story
on the importance of diversifying clinical trials asserting that “[a]
COVID-19 vaccine will work only if trials include Black
participants[.]”154 Many other major news outlets, including the Wall
Street Journal,155 The New York Times,156 and The Washington Post157
published stories and opinion pieces on the importance of diversifying
COVID-19 vaccine trials.
The pharmaceutical industry was responsive to these calls. In May
2020, the Chief Diversity Officer and the Head of U.S. Medical Affairs
for Genentech issued a “call for more inclusive COVID-19 research.”158
Testifying before a U.S. House Subcommittee in July 2020, a
representative from Johnson & Johnson declared that it “is committed
to robust representation of diverse populations in our studies.”159 The
more-people-of-color-needed-in-covid-19-vaccine-trials [https://perma.cc/
HJL6-YCGW].
153. Adam Feuerstein, Damian Garde, & Rebecca Robbins, Covid-19 Clinical

Trials Are Failing to Enroll Diverse Populations, Despite Awareness
Efforts, STAT (Aug. 14, 2020), https://www.statnews.com/
2020/08/14/covid-19-clinical-trials-are-are-failing-to-enroll-diversepopulations-despite-awareness-efforts/ [https://perma.cc/4PZ8-FRVV].
154. Curtis Bunn, A COVID-19 Vaccine Will Work Only if Trials Include
Black Participants, Experts Say, NBC NEWS (June 7, 2020),
https://www.nbcnews.com/news/nbcblk/covid-19-vaccine-will-onlywork-if-trials-include-black-n1228371 [https://perma.cc/56BN-K2GZ].
155. Brian Gormley, Researchers Look for Ways to Make Drug Trials More
Diverse, WALL ST. J. (Mar. 28, 2021), https://www.wsj.com/
articles/researchers-look-for-ways-to-make-drug-trials-more-diverse11616885108 [https://perma.cc/K3SE-6ZEP].
156. Wayne A.I. Frederick et al., We Need to Recruit More Black Americans
in Vaccine Trials, N.Y. TIMES (Sept. 11, 2020), https://
www.nytimes.com/2020/09/11/opinion/vaccine-testing-blackamericans.html [https://perma.cc/K6S7-AC8Z].
157. Karen Bass, People of Color Are Disproportionately Affected By Covid19. Yet They Are Underrepresented in Vaccine Trials, WASH. POST (Sept.
1, 2020), https://www.washingtonpost.com/opinions/karen-bass-covidtrials-people-of-color-underrepresented-/2020/09/01/9f5c8502-ebae-11eaab4e-581edb849379_story.html [https://perma.cc/RBH6-CXBD].
158. Quita Highsmith & Jamie Freedman, A Call For More Inclusive COVID19 Research: Tackling Disparities During a Pandemic, GENENTECH (May
22, 2020), https://www.gene.com/stories/a-call-for-more-inclusive-covid19-research [https://perma.cc/V5Q9-RMAQ].
159. Pathway to a Vaccine: Efforts to Develop a Safe, Effective, and Accessible

COVID-19 Vaccine Virtual Hearing Before the Subcomm. on Oversight
and Investigations of the H. Comm. on Energy and Commerce, 116th
Cong. (2020) (statement of Macaya Douoguih, Head of Clinical
Development and Medical Affairs, Janssen Vaccines and Prevention,
Johnson & Johnson).
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major trade group PhRMA issued a statement in October, recognizing
that “achieving clinical trials that include diverse populations presents
an ongoing challenge[,]” and affirmed its commitment “to enhance the
diversity of clinical trial participants[.]”160 In presenting data on its
COVID-19 vaccine to the FDA for approval in December, Pfizer
emphasized “the importance of conducting the study in people of
color,”161 and asserted that “from the very start [it was] focused on
targeting in recruitment from racial and ethnic minorities.”162 Moderna
was so responsive to these concerns that it actually paused its clinical
trial in October in order to increase minority enrollment.163 By April
2021, the industry trade publication Scrip was even promoting the
Twitter hashtag “#ClinicalTrialsSoWhite.”164
Concerns for clinical trial diversity were also evident throughout
the FDA review process for both the Pfizer and the Moderna vaccines.
Pfizer reported that, of a total clinical trial population of 40,277
subjects, 3929, or 9.8%, were Black and 10553 or 26.2% were
Hispanic/Latino.165 Moderna similarly reported that of its 30,351
clinical trial subjects approximately 10% were Black and 21% Hispanic
or Latino.166 A number of people and organizations submitting

160. Principles on Conduct of Clinical Trials Communication of Clinical Trial
Results, PHRMA (Oct. 14, 2020), https://www.phrma.org/-/media/
Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/P-R/
PhRMAPrinciples-of-Clinical-Trials-FINAL.pdf.
161. U.S. FOOD & DRUG ADMIN., 162ND VACCINES AND RELATED BIOLOGICAL
PRODUCTS ADVISORY COMMITTEE MEETING OF THE U.S. FOOD AND DRUG
ADMIN. CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (2020)
[hereinafter 162ND MEETING OF VACCINES], https://www.fda.gov/
media/144859/download [https://perma.cc/G8LX-YBYJ] (transcript of
the statement of William Gruber, Pfizer Senior Vice President of Vaccine
Clinical Research & Development available at 211).
162. Id. (available at 352).
163. Julie Steenhuysen, Moderna Vaccine Trial Contractors Fail to Enroll
Enough Minorities, Prompting Slowdown—Sources, REUTERS (Oct. 6,
2020), https://www.reuters.com/article/idUSL1N2GW1F0 [https://
perma.cc/HFY2-FUJT].
164. @PharmaScrip, TWITTER (Apr. 17, 2021), https://twitter.com/
PharmaScrip/status/1383329928867762180
[https://perma.cc/TA9VMFK3].
165. U.S. FOOD & DRUG ADMIN., VACCINES AND RELATED BIOLOGICAL
PRODUCTS ADVISORY COMMITTEE MEETING, PFIZER-BIONTECH COVID19 VACCINE BRIEFING DOCUMENT (2020) [hereinafter PFIZER-BIONTECH
BRIEFING DOCUMENT], https://www.fda.gov/media/144245/download
[https://perma.cc/32EP-JVTS].
166. U.S. FOOD & DRUG ADMIN., VACCINES AND RELATED BIOLOGICAL
PRODUCTS ADVISORY COMMITTEE MEETING, MODERNATX, INC.,
PRESENTATION FOR EMERGENCY USE AUTHORIZATION (EUA)
APPLICATION
FOR
MRNA-127
(2020),
https://www.fda.gov/
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comments to the FDA on the proposed vaccines also raised concerns
about clinical trial diversity. For example, the American Academy of
Pediatrics cautioned that “the population studied must reflect the racial
and ethnic diversity of the US population[;]”167 the Associate Director
of Health Policy for the National Consumers League requested “that
the FDA continue to prioritize vaccine clinical trial data that reflects
diversity[;]”168 and the Executive Director of the National Women’s
Health Network flatly asserted that “there were not enough Black and
Indigenous people included in the Moderna phase 3 trial.”169 In response,
Dr. William Gruber, Senior Vice President of Pfizer Vaccine Clinical
Research and Development, assured the FDA review committee that
“[w]e also recognized the importance of conducting the study in people
of color; so we have adopted an approach that assures a diverse racial
and ethnicity profile.” 170
Such calls to diversify clinical trials for COVID-19 vaccines at times
came to take on the character of a sort of diversity panic. Horrible
things, it seemed, would happen if clinical trials did not sufficiently
represent diverse populations. The vaccine would not work; it would
not be safe; it would not be trusted. Only through diversity could such
catastrophes be avoided. Upon close inspection, however, such claims
were often based on questionable assumptions, incomplete data, and
problematic definitions of such basic concepts as “diversity” and
“representation.”
Calls to diversify the clinical trials for COVID-19 vaccines were
repeated, widespread, and persistent. Rationales for diversifying clinical
trials, and more specifically diversifying them by race, can be organized
into three basic (and sometimes overlapping) categories: biological,
social, and political. Biological rationales generally had to do with
concerns for safety, efficacy, and generalizability of trial results. Social
rationales revolved around addressing issues of trust and vaccine
hesitancy. Lastly, political rationales involved commitments to address
equity in access to care and therapeutics.
media/144583/download [https://perma.cc/BR76-PD97] (presented by
Tal Zaks, Chief Medical Officer).
167. Letter from Mark Del Monte, Chief Exec. Officer, Am. Acad. of
Pediatrics, to Hana El Sahly, Chair, U.S. Food & Drug Admin.: Vaccines
& Biological Products Advisory Comm. & Prabhakara Atreya, Director,
U.S. Food & Drug Admin: Div. of Sci. Advisors & Consultants (Oct. 15,
2020) (on file with the Am. Acad. of Pediatrics).
168. 162ND MEETING OF VACCINES, supra note 161 (available at 172).
169. Letter from Cynthia A. Pearson, Executive Director, National Women’s
Health Network, to U.S. Food & Drug Admin. Vaccines and Related
Biological Products Advisory Committee (Dec. 17, 2020), https://
www.regulations.gov/comment/FDA-2020-N-2242-0379
[https://perma.cc/5A4X-7P3].
170. 162ND MEETING OF VACCINES, supra note 161, at 211.

181

Health Matrix · Volume 32 · 2022
Diversity's Pandemic Distractions

III. UNPACKING THE BIOLOGICAL RATIONALES FOR DIVERSE
VACCINE CLINICAL TRIALS
Biological, social, and political rationales for diversifying clinical
trials may be reasonable, but only if clearly articulated and justified.
Too often when race is introduced into the field of biomedicine these
rationales become intertwined, confused, and conflated in a manner
that threatens to reify race as genetic and divert attention away from
the social and political bases of health inequities.
A. Empirical Bases for Concerns about Diversity

Calls to diversify vaccine clinical trials focused on the importance
of obtaining data that showed the vaccines were safe and effective in
all relevant racial and ethnic groups. The Democratic Senators’ April
20, 2020 letter to leading pharmaceutical CEOs was very clear about
this, ominously quoting from a statement issued by the Johns Hopkins
University Science Policy Group in 2017. The quote read:
Inequitable research can lead to dangerous outcomes for those
who are not represented in clinical trials. Drugs including
chemotherapeutics,
antiretrovirals,
antidepressants,
and
cardiovascular medications have been withdrawn from market
due to differences in drug metabolism and toxicity across race and
sex. 171

Months later, in answering “Key Questions” on “Racial Diversity
within COVID-19 Vaccine Clinical Trials[,]” researchers from the
Kaiser Family Foundation asserted that “[d]iversity within clinical
trials for a COVID-19 vaccine helps ensure safety and effectiveness[.]”172
Significantly, this report also noted that “[d]iverse racial/ethnic
representation in COVID-19 vaccine trials is important because drugs
and vaccines can differentially affect groups reflecting variation in
underlying experiences and environmental exposure.”173
Such sensitivity to the complex relationship between race and nongenetic factors in immune response stands in marked contrast to many
media reports, such as one by NBC News from June 2020, which quoted
a retired pulmonologist who asserted that “[g]enetics related to racial
differences make it essential that we be involved in broad-based and
diverse clinical trials of medications and vaccines.” 174 The NBC report
171. Menendez et al., supra note 141 (citing Leah Cairns, Diversity in Clinical
Trials, JOHNS HOPKINS SCI. POL. GROUP (Sept. 6, 2017), https://
www.jhscipolgroup.org/blog-1/2017/9/6/diversity-in-clinical-trials
[https://perma.cc/U3LP-LV6K]).
172. Artiga et al., supra note 148.
173. Id.
174. Bunn, supra note 154.
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then flatly stated this meant that “[a] vaccine might not work in African
Americans if African Americans do not participate in the clinical trials
to create the drug.”175
Not all media reports quite so baldly geneticized race. A quote from
a story in StatNews by UC San Francisco oncologist Hala Borno is more
typical of media reporting; Borno stated: “I think that if we do not
ensure diversity in these Covid-19 clinical research studies, we may
ultimately render interventions, whether it be drug or vaccines, that do
not uniformly demonstrate efficacy across populations, or have side
effects that we only capture later on.”176 A more recent study of
inclusion in vaccine trials published in JAMA Network Open asserted:
“Historically, clinical trials have lacked equitable inclusion of people
identifying as members of racial/ethnic minority groups and female and
older individuals. When people with diverse backgrounds are not
adequately represented, treatments shown to be effective in trials may
not be generalizable to or effective for all populations.”177 Similarly,
Paulette Chandler, a primary care physician and lead of community
engagement and education for COVID-19 vaccine trials at Boston’s
Brigham and Women’s Hospital stated in September 2020 that “unless
we have a diverse group of people involved in the trial, we will not be
able to generalize our findings to every group.”178
The theme is clear and consistent. There is an assumption that
essential biological racial difference is somehow directly related to how
a vaccine works – either in terms of its efficacy or its side effects.
References to “generalizability” are particularly concerning because,
without explicitly invoking the idea of racial differences, they imply
that results from trials conducted in people of one race simply cannot
be extrapolated to people of another race. The problem is that there
was little or no evidence to support these race-specific concerns about
safety, efficacy, or generalizability, and certainly not sufficient evidence
to warrant major efforts to reconfigure (and perhaps delay) clinical
trials in a time of pandemic emergency.
While diversifying clinical trials has long been a concern of both the
federal government and an array of biomedical institutions, prior to
2020 there had been relatively little discussion of the need or importance
of diversity in vaccine trials specifically. Just over two years before the
COVID-19 outbreak, the World Health Organization issued a report
175. Id.
176. Feuerstein, Garde, & Robbins, supra note 153.
177. Laura E. Flores et al., Assessment of the Inclusion of Racial/Ethnic
Minority, Female, and Older Individuals in Vaccine Clinical Trials,
4 JAMA NETW. OPEN, at 3 (2021).
178. Kristin Toussaint, COVID-19 Vaccine Trials Are Being Undermined By a
Lack of Diversity, FAST CO. (Sept. 28, 2020), https://www.
fastcompany.com/90555722/why-covid-19-vaccine-trials-still-need-morediversity [https://perma.cc/5DQE-4YBY].
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titled “Design of vaccine efficacy trials to be used during public health
emergencies—points of considerations and key principles”179 that made
no reference to race at all, and only one reference to ethnicity in the
context of considering vulnerable groups in potential need of protection
from exploitation by researchers. 180 An article titled “Design of vaccine
efficacy trials during public health emergencies,” published in Science
Translational Medicine in July 2019 on the eve of the COVID-19
outbreak, similarly had no mention of race or ethnicity in relation to
issues of safety, efficacy, of generalizability of trial results.181 Another
lengthy review article published in 2019 examining “factors that
influence the immune response to vaccination” does mention studies of
ethnic variability in response to vaccines in one sentence out of 30 pages
of text.182 However, the studies it references tend to involve not large
racial groups, but localized ethnic populations, such as different ethnic
groups within Guatemala or a particular region of China.183 None of the
cited studies found any difference in safety or efficacy based on race or
ethnicity.184 To the contrary, instead of focusing on race, the bulk of
the Zimmerman and Curtis article is devoted to examining factors such

179. Design of Vaccine Efficacy Trials to Be Used During Public Health
Emergencies – Points of Considerations and Key Principles, WORLD
HEALTH ORG., https://www.who.int/docs/default-source/blue-print/
working-group-for-vaccine-evaluation-(4th-consultation)/ap1-guidelinesonline-consultation.pdf [https://perma.cc/2SYQ-RUX5] (last visited Feb.
20, 2022).
180. Id.
181. Natalie E. Dean et al., Design of Vaccine Efficacy Trials During Public
Health Emergencies, 11 SCI. TRANSL. MED. 499, 499 (2019).
182. Petra Zimmermann & Nigel Curtis, Factors That Influence the Immune
Response to Vaccination, 32 CLIN. MICROBIOL. REV., at 1, 5 (2019).
183. Id. at 37. It also cites three studies by one researcher who uses broader
racial groups to identify variable immune response to certain vaccines but
without identifying any underlying genetic mechanism to explain the
difference or finding any difference in safety or efficacy. Id.
184. Three of the articles cited by the study, all with the same lead author, do
purport to find racial difference in immune response to certain vaccines,
but these findings are both limited and equivocal. As one of these studies
states: “Ethnicity and race-specific data on infectious disease
susceptibility and clinical course, and/or differences in immune responses
to pathogens and vaccines is limited in the literature, and the underlying
mechanisms for the reported observations are still unknown,” and goes on
to note that “the observed statistically significant effects (cytokine
response differences) in our study are relatively small and there is no
known correlate of protection for vaccinia-specific cell-mediated
immunity.” Iana H. Haralambieva et al., Race and Sex-Based Differences

in Cytokine Immune Response to Smallpox Vaccine in Healthy
Individuals, HUMAN IMMUNOL., 2013, at 1, 4.
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as co-morbidities, behavior, nutrition, environmental exposures and the
nature of the vaccine itself and its administration.185
As for the three COVID-19 vaccines that were ultimately developed
in the United States during 2020 and approved by the FDA —all found
to have a similar safety and efficacy profile across all racial subgroups.
This can largely be explained by the simple fact that race is not genetic.
The FDA reported that the first approved vaccine, developed by Pfizer,
showed efficacy to be “consistent across various subgroups, including
racial and ethnic minorities,”186 and its “safety profile” to be “generally
similar across age groups, genders, ethnic and racial groups.”187 The
FDA came to similar conclusions regarding the Moderna vaccine,
finding vaccine efficacy among racial and ethnic “subgroups” to be
similar to that “seen in the overall study population”188 and identifying
“no specific safety concerns . . . in subgroup analyses by age, race, [or]
ethnicity.”189 Finally, for the Johnson & Johnson vaccine, the FDA
concluded that efficacy “among the subgroups (age, comorbidity, race,
ethnicity) appears to be similar to the [vaccine efficacy] in the overall
study population,”190 and “there were no specific safety concerns
identified in subgroup analyses by age, race, ethnicity, medical
comorbidities, or prior SARS-CoV-2 infection.” 191
Given the consistency of these results (not to mention their
concordance with experience from previous vaccines) it is, perhaps,
worth revisiting some of the early, urgent calls to diversify the COVID19 vaccine trials. What were their rationales and what sort of evidence
did they present to support their concerns? Noteworthy in this regard
is the April 20, 2020 letter from the sixteen Democratic U.S. Senators
to leading pharmaceutical CEOs calling for diversity in vaccine clinical
trials. Coming from such prominent and powerful politicians, relatively
early in the pandemic, it set a powerful frame for conceptualizing the
clinical trial process. Of particular force was the quotation, referenced

185. Zimmermann & Curtis, supra note 182, at 3.
186. PFIZER-BIONTECH BRIEFING DOCUMENT, supra note 165.
187. Id.
188. U.S. FOOD & DRUG ADMIN., VACCINES AND RELATED BIOLOGICAL
PRODUCTS ADVISORY COMMITTEE MEETING, MODERNA COVID-19
VACCINE
BRIEFING
DOCUMENT
(2020),
https://www.fda.gov/
media/144434/download [https://perma.cc/A249-CXLK].
189. Id.
190. U.S. FOOD & DRUG ADMIN., VACCINES AND RELATED BIOLOGICAL
PRODUCTS ADVISORY COMMITTEE MEETING, JANSSEN AD26.COV2.S
VACCINE FOR THE PREVENTION OF COVID-19 BRIEFING DOCUMENT (2021)
[hereinafter JANSSEN BRIEFING DOCUMENT], https://www.fda.gov/
media/146217/download [https://perma.cc/MVT9-6XYQ].
191. Id.

185

Health Matrix · Volume 32 · 2022
Diversity's Pandemic Distractions

above, to a statement issued by the Johns Hopkins University Science
Policy Group in 2017. The full paragraph in the letter states:
Alarming research shows that although “African Americans
represent 12% of the United States population, they make up only
5% of all clinical trial participants. Only 1% of clinical trial
participants were Hispanic, though they comprise 16% of the
national population. “As a result, “[i]nequitable research can lead
to dangerous outcomes for those who are not represented in
clinical trials. Drugs including chemotherapeutics, antiretrovirals,
antidepressants, and cardiovascular medications have been
withdrawn from market due to differences in drug metabolism
and toxicity across race and sex.”192

Let us unpack this reference and the work it did in the Senators’
letter. First, even on its face, the quoted passage refers to drugs, not
vaccines. More specifically, it refers to drug metabolism and toxicity.
The biological mechanisms underlying drug metabolism and immune
response, while often related, are distinct.193 Variance in drug
metabolism is common and is affected by many things, including diet,
other medications, comorbidities, and genetics. For any given drug
there will be a standard or normal rate of metabolization, and there
will also be a certain range of individuals who metabolize the drug more
quickly or more slowly than the norm. This can be particularly
important for determining proper dosage. Rapid metabolizers might
require a higher dose for the drug to be effective, while slower
metabolizers might need a lower dose because the drug stays in their
system longer. When slow metabolizers receive normal or high doses,
this can cause toxic reactions. Several drugs’ labels mention race or
ethnicity as a factor in determining whether someone is likely a rapid
or slow metabolizer, but this is a crude proxy for prediction of the rate
of metabolization.194 It is important to note that there is no clear
concordance of race and drug metabolization. Instead, in some cases,
there is merely an observation that for some drugs certain racial groups
may have, on average, a higher frequency of rapid or slow metabolizers
than others. In any event, drug metabolization is not directly related
to the immune response provoked by a vaccine. 195
192. Menendez et al., supra note 141 (citing Cairns, supra note 171).
193. See, e.g., Gökhan S. Hotamisligil, Inflammation, Metaflammation and
Immunometabolic Disorders, 542 NATURE 177, 177 (2017).
194. S. U. Yasuda, L. Zhang, & S-M. Huang, The Role of Ethnicity in

Variability in Response to Drugs: Focus on Clinical Pharmacology
Studies, CLIN. PHARMACOL. THER., 2008, at 1, 2-3.
195. A classic example of this is the widely prescribed anti-coagulant drug
warfarin, which is commonly prescribed to patients who are at risk of
developing blood clots, such as persons with atrial fibrillation, recurrent
strokes, deep venous thrombosis, pulmonary embolism, or those who have
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Second, the Johns Hopkins statement cited by the Senators is itself
only a blog post that, in turn, cites a study from the Journal of
Women’s Health to support its statement.196 This study197 does not
support the Johns Hopkins assertion that many drugs “have been
withdrawn from market due to differences in drug metabolism and
toxicity across race and sex.” Rather, it states that “several drugs have
been withdrawn from the market over the last two decades because of
sex-based adverse events,” and then goes on to merely observe that
“with regard to race and ethnicity, a number of studies have found
variations in drug metabolism and toxicity” in various drugs. Again,
this is without reference to any vaccines.198 This is not an insignificant
difference. It refers only to withdrawing drugs for sex-based differences,
not race. For race, it simply restates the widely observed phenomenon
that for certain drugs there may be different frequencies of rapid and
slow metabolizers in different ethnic groups.
This second study itself references a third study to support its
statement about sex-based drug withdrawals.199 That study, published
in the European Journal of Clinical Pharmacology, observed that
“[s]everal publications indicate that the female gender experiences a
higher incidence of adverse drug reactions (ADRs) than does the male
gender. The reasons, however, remain unclear. Gender-specific
differences in the pharmacokinetic and pharmacodynamic behaviour of

received heart valve replacements. It is difficult to calibrate the right dose
for an individual patient because warfarin has a narrow therapeutic
window of efficacy and a wide-range of inter-individual variability in
response; that is people tend to metabolize the drug at different rates. If
you are fast metabolizer and do not get a high enough dose, you risk
developing blot clots. If you are a slow metabolizer and get too high a
dose, you risk having a dangerous hemorrhage. Many studies over the
years have noted correlations between certain broad ethnic or racial
groups and likelihood of being a rapid or slow metabolizer. Drug labels
have noted this for years. In the past decade specific genetic variations
have been identified that greatly affect warfarin metabolization and
dosing algorithms have been developed to replace the cruder use of racial
categories with genetic testing. Nonetheless, the use of race as a crude
proxy in drug dosing for warfarin (and some other drugs) persist. See
KAHN, supra note 64, at 157-92.
196. Cairns, supra note 171.
197. Meghan Coakley et al., Dialogues on Diversifying Clinical Trials:

Successful Strategies for Engaging Women and Minorities in Clinical
Trials, 21 J. WOMENS HEALTH 713, 714 (2012).
198. Id. at 714-15 (emphasis added).
199. Id. at 714 (citing Y. Zopf, C. Rabe, A. Neubert et al., Women Encounter
ADRs More Often Than Do Men, 64 EUR. J. CLIN. PHARMACOL. 999
(2008)).
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drugs could not be identified as an explanation.”200 The study concluded
that while “our data confirm the higher risk of ADRs among female
subjects compared with a male cohort . . . [n]o single risk factor could
be identified.” 201 This study, while confirming gender-specific
differences in drug response, made no mention of withdrawing drugs
from the market.
This is not to say the claim regarding FDA concerns with sex-based
differences in drug response is wholly without merit. Indeed, a 2001
General Accounting Office study (not cited by the Johns Hopkins
statement) did find that eight of the ten drugs withdrawn from the
market between 1997 and 2000 posed higher risks for women.202 Even
so, there is a marked difference between finding that the drugs
withdrawn happened to have a higher risk for women, and determining
that the drugs were withdrawn because they had a higher risk for
women. Still none of this speaks to alleged race-based differences in
safety or efficacy as grounds for drug withdrawal, and also does not
speak to race-based differences in vaccine response. In short, despite
what the letters from the Senators claimed, existing evidence supported
the conclusion of bioethicists Angela Ballantyne and Agomoni GanguliMitra that, “on balance there is no biological imperative to achieve
representative recruitment of minoritized populations in COVID
vaccine trials.”203
The example of the Senators’ letter illustrates how the casual
blurring of boundaries and elision of distinctions can lead to the
reification of racial difference as genetic. Moreover, as is made evident
by the 2019 review of factors influencing vaccine response referenced
above,204 non-genetic behavioral, environmental, and social factors
certainly dwarf any possible importance of race for assessing variable
vaccine response. A vaccine cannot elicit any response in someone who
is either unable to access it or unwilling take it.
The questionable empirical basis for concerns about racial variance
in vaccine efficacy or safety is only the first issue that needs to be
unpacked in the realm of biological rationales for diversifying clinical
200. Y. Zopf, C. Rabe, A. Neubert et al., Women Encounter ADRs More Often
Than Do Men, 64 EUR. J. CLIN. PHARMACOL. 999, 999 (2008) (emphasis
added).
201. Id.
202. Letter from Janet Heinrich, Director Health Care – Public Health Issues,
U.S. General Accounting Office, to Senators Tom Harkin, Olympia J.
Snowe, and Barbara A. Mikulski and Representative Henry A. Waxman
(Jan. 19, 2001), https://www.gao.gov/assets/gao-01-286r.pdf [https://
perma.cc/A8AY-JTAK].
203. Angela Ballantyne & Agomoni Ganguli-Mitra, To What Extent Are Calls

for Greater Minority Representation in COVID Vaccine Research
Ethically Justified?, 21 AM. J. BIOETHICS 99, 99 (2021).
204. Zimmermann & Curtis, supra note 182, at 3.

188

Health Matrix · Volume 32 · 2022
Diversity's Pandemic Distractions

trials. The second issue is what exactly was meant by “diversity” when
diversity was called for in clinical trials for COVID-19 vaccines.
B. What Is Meant By “ Diversity” in Vaccine Trials?

Calls to “diversify” the COVID-19 vaccine clinical trials
typically invoked, in a commonsense fashion, the basic Census
categories of race and ethnicity (i.e., White, Black, Asian/Pacific
Islander, American Indian/Alaska Native, Hispanic/Non-Hispanic) that
have their foundation in a 1997 Directive from the Office of
Management and Budget.205 These categories structured the 1993 NIH
Revitalization Act directive to increase diversity in clinical trials, and
have since become the default categories for much of biomedical
research and regulation.206 They are also generally the same categories
that were used to identify and trace racial disparities in the impact of
COVID-19.
But why the focus on race in the first place? Often in studies
arguing for the relevance of race as a genetic category in biomedical
research, the authors argue that race is an apt proxy for continental
genetic ancestry.207 This sort of conceptualization of diversity was
evident in some of the studies of the possible genetic underpinnings to
COVID-19 disparities, particularly those involving the global
distribution of HLA haplotypes.208 Yet, such efforts to capture ancestral
genetic diversity were not prominent in discussions of COVID-19
vaccine trials. Presentations before the FDA during the review
processes for the various vaccines generally did not engage issues of
genetic diversity but simply focused on the demographic Census
categories.
Apparently, then, when it came to calls to diversify vaccine trials,
clinical trial designers simply assumed, without evidence, that
demographic categories of race had some biologic relevance to vaccine
performance. One might just as easily have called for diversifying
vaccine trials to ensure adequate representation of left-handed people.
Left-handedness as a phenotype is perhaps more closely related to

205. Revisions to the Standards for the Classification of Federal Data on Race
and Ethnicity, 62 Fed. Reg. 58,782 (Oct. 30, 1997).
206. See generally, KAHN, supra note 64, at 25-47; EPSTEIN, supra note 133, at
74-93.
207. See e.g., Esteban González Burchard et al., The Importance of Race and
Ethnic Background in Biomedical Research and Clinical Practice, 348
NEW ENG. J. MED. 1170, 1170 (2003); Luisa N. Borrell et al., Race and
Genetic Ancestry in Medicine – A Time for Reckoning with Racism, 384
NEW ENG. J. MED. 474, 474 (2021).
208. Nguyen et al., supra note 46; Debnath et al., supra note 46; Langton et
al., supra note 46.
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genetic difference than is race.209 In the United States about 13% of the
population is left-handed.210 Roughly the same percentage of the
population is Black; thus, if researchers are concerned with genetically
diverse representation, why was nobody talking about this or any
number of other possible population group differences? Perhaps because
we do not have a centuries-old biomedical tradition of trying to discern
biological differences between “righties” and “lefties” as a means to
justify social hierarchy or explain away disparities. Of course,
historically, being left-handed has also been stigmatized, but the
consequences of such stigmatization have always been understood to be
social in character and not due to any underlying genetic difference.
Hence, no need to enroll lefties in clinical trials in proportion to their
representation in the population. Black people, however, are another
story. As the marked disparities in COVID-19’s impact were attributed
“in part” to some presumed, if unidentified, genetic differences – that
is, as the consequences of the stigmatized characteristic were attributed
to biology instead of society – there emerged a purported biological
rationale to single out race, among a wide range of possible demographic
characteristics, as essential for representation in vaccine trials.
As we look more closely at invocations of the need for diversity, we
see further refinements of the basic Census categories that elaborate the
biological rationales for the call. For example, in its November 2020
Guidance for Industry on “Enhancing the Diversity of Clinical Trial
Populations,” the FDA emphasized the importance of enrolling subjects
who will better reflect the population most likely to use the drug,211 i.e.,
those affected with the condition the drug is meant to treat. However,
the same Guidance also makes it clear the “sponsors should enroll
participants who reflect the characteristics of clinically relevant
populations with regard to age, sex, race, and ethnicity . . . [because]
analyzing data on race and ethnicity may assist in identifying
population-specific signals.” 212 This echoes concerns about possible
racial differences in response to some drugs; however, as discussed, in
the response to COVID-19, we are not dealing with a drug, nor with a
209. Genes Associated with Left-Handedness Linked with Shape of the Brain’s
Language Regions, OXFORD U. (Sept. 5, 2019), https://
www.ox.ac.uk/news/2019-09-05-genes-associated-left-handedness-linkedshape-brains-language-regions [https://perma.cc/7V5T-9CP3].
210. Niall McCarthy, The Countries with the Most Left-Handed People,
STATISTA (Feb. 4, 2020), https://www.statista.com/chart/20708/rate-ofleft-handedness-in-selected-countries/ [https://perma.cc/8GSS-4FUH].
211. Enhancing the Diversity of Clinical Trial Populations, 85 Fed. Reg. 71,654
(Nov. 10, 2020).
212. Id; U.S. FOOD & DRUG ADMIN., ENHANCING THE DIVERSITY OF CLINICAL
TRIAL POPULATIONS — ELIGIBILITY CRITERIA, ENROLLMENT PRACTICES,
AND TRIAL DESIGNS GUIDANCE FOR INDUSTRY (2020), https://
www.fda.gov/media/127712/download [https://perma.cc/44QY-MCH].
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“population most likely to use the drug.” Rather, we are dealing with
a vaccine, and the population most likely to use it is – ideally –
everyone.
More specific to the COVID-19 vaccine trials was the idea that the
trials must be representative of communities bearing the heaviest
disease burden or at the highest risk of contracting the disease. These
categories certainly have a public health logic to them, but they can
also be moving targets during a period of emergent crisis. Certainly, as
in the case of COVID-19 with its well-documented disparate impact in
the United States, they may loosely map onto racial groupings. Thus,
for example, in its June 2020 Guidance to Industry on “Development
and Licensure of Vaccines to Prevent COVID-19,” the FDA, when
urging the “inclusion of diverse populations” in clinical trials, “strongly
encourage[d] the enrollment of populations most affected by COVID19, specifically racial and ethnic minorities.”213 In order to evaluate
“vaccine safety and efficacy,” the Guidance encouraged “adequate
representation of elderly individuals and individuals with medical
comorbidities.” 214 The distinctions between the two categories of
inclusion are significant. This is the only place race is mentioned in the
Guidance, and it is not directly connected to concerns of safety or
efficacy. The rationale for racial inclusion in the Guidance is that it is
a marker of populations “most affected” by COVID-19. Similarly, Dr.
Ann Falsey of the University of Rochester School of Medicine further
contextualized diversity as a function more of risk than of race when
she told a journalist at JAMA: “[w]e are thinking very hard about not
only how to get a diverse population that reflects the US population
but also people at high risk—postal workers, home health workers, you
name it.”215
In comments submitted to the FDA regarding its review of the
Pfizer vaccine, the Infectious Diseases Society of America emphasized
that “COVID-19 vaccines should be adequately studied in populations
that have been disproportionately impacted by the pandemic and who
face disparities in care, including the elderly; individuals with chronic
conditions; and Black/African American, Indigenous, Latinx, and other
communities of color.”216 Here disparate impact is connected with access
to care. There is, in other words, no explicit biological rationale for
racial inclusion. Rather, in these examples we see the rationale for using
race as being grounded in concepts of risk or concerns for equity. It is
213. GUIDANCE FOR INDUSTRY, supra note 145.
214. Id.
215. Jaklevic, supra note 143.
216. Comment Letter on Vaccines and Related Biological Products Advisory
Committee Notice, INFECTIOUS DISEASES SOC’Y AM. (Dec. 4, 2020),
https://www.regulations.gov/comment/FDA-2020-N-1898-0105 [https://
perma.cc/R5FQ-M7AU].
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thus possible to make appeals for diversity in ways that do not assert
or imply that racial difference is genetic. Nonetheless, given that at this
time many studies were being published arguing that genetic
susceptibility to COVID-19 varied by race, it is also possible that this
framing reflected those biologized understandings of racial disparities in
COVID-19.
Other calls for diversity in clinical trials more directly geneticized
race. In a blog posting by Henry Ford Health System, Dr. Paul Kilgore,
co-principal investigator for its Johnson & Johnson COVID-19 vaccine
trial, declared: “When people have different genetic and biologic
makeup, their bodies can produce antibodies differently. This means to
ensure a vaccine will protect people of all ethnic groups, we need to
make sure everyone is fully represented in clinical trials.”217 We also see
an interest in disparate impact blur into presumptions of essential
biological difference in the concerns expressed by Dr. Anna Durbin,
principal investigator at the Johns Hopkins Center for Immunization
Research, who insisted that racial diversity was necessary to “to make
sure it works in the groups most affected by COVID-19.”218 The focus
on equity is laudable, and concerns for safety and efficacy are
reasonable, but it is difficult to keep these issues separate and distinct.
In juxtaposing the two in relation to race, the reification of race as
genetic becomes almost inevitable, especially in a biomedical culture
suffused with understandings of race as an essential biological
category.219
Calls to diversify COVID-19 vaccine trials also extended to hiring
the health workforce responsible for carrying out the trials. The general
idea was that upstream representation of racial minorities in the health
professions would increase downstream willingness to participate in
clinical trials. For example, in discussing COVID-19 vaccine trials on
National Public Radio, Renee Mahaffey Harris, president of the Center
for Closing the Health Gap, noted that “due to the fact that COVID19 has had a disproportionate impact to Black and Latino people across
this country, it is more paramount than ever that the trials be reflective
of a bigger proportion of Black and Latino people.” She then went on
to assert the importance of having more Black and Latino doctors and
researchers represented at “the early part of creating the trial.”220 In
217. Why Is Diversity So Important In Vaccine Trials?, supra note 147.
218. Brennen Jensen, Boosting Diversity in COVID-19 Vaccine Clinical Trials,
HOPKINS BLOOMBERG PUB. HEALTH MAG. (Nov. 9, 2020), https://
magazine.jhsph.edu/2020/boosting-diversity-covid-19-vaccine-clinicaltrials [https://perma.cc/J596-ZG38].
219. See generally CATHERINE BLISS, RACE DECODED (2020); ANN MORNING,
THE NATURE OF RACE: HOW SCIENTISTS THINK AND TEACH ABOUT HUMAN
DIFFERENCE (2011); Vyas, Eisenstein, & Jones, supra note 116.
220. More People Of Color Needed In COVID-19 Vaccine Trials, NAT’L PUB.
RADIO (Aug. 23, 2020), https://www.npr.org/2020/08/23/905181731/
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October 2020, the Pharmaceutical Research and Manufacturers of
America (PhRMA) issued “Principles on Conduct of Clinical Trials
Communication of Clinical Trial Results,” in which it declared that
“[e]nhancing meaningful representation of diverse participants in
clinical trials would help provide information about drug response and
measures of safety and efficacy in populations that have been
historically under-represented and under-studied, in particular Black
and Brown people.”221 PhRMA went on to assert that to achieve this
goal it was necessary to “enhance[] diversity among clinical trial
investigators.”222 This shows both the flexibility and ambiguity of the
concept of diversity. In relation to clinical trial subjects, diversity was
often used in a way that presumed essential biological differences among
racial groups. Yet it was often invoked by the same actors to apply in
a wholly social sense to the need to diversify the workforce. The issue
here is not that such uses of diversity are wrong or incorrect, but that
it is a slippery concept that ranges across social and biological domains.
The concept of diversity needs to be employed carefully in contexts
where the conflation or confusion of social and biological conceptions of
racial difference are likely to occur.

IV. HOW MUCH DIVERSITY IS ENOUGH?
Once you determine that you want or need representation from
diverse racial groups in clinical trials, the next question becomes just
how much diversity is enough? In terms of biomedical concerns, one
generally wants to enroll “enough” people to ensure statistically robust
results showing safety and efficacy in any given “population.” This is,
in theory at least, what has been driving calls for inclusion going back
to the 1993 NIH Revitalization Act.223 When it comes to racially marked
populations, concepts of what constitutes adequate representation vary
significantly. Such variance may be due, in part, to the particular
rationale for diversity one is seeking to serve. It may also simply be due
to a lack of attention as to why racial diversity may or may not matter
in a vaccine trial. Clarifying such issues matters because it allows us to
differentiate among biological, social, and political rationales for
diversity and ensure that socio-political concerns for diversity do not

more-people-of-color-needed-in-covid-19-vaccine-trials [https://perma.cc/
4ENB-VLDB].
221. Principles on Conduct of Clinical Trials Communication of Clinical Trial
Results, PHRMA (Oct. 14, 2020), https://www.phrma.org/-/media/
Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/P-R/
PhRMAPrinciples-of-Clinical-Trials-FINAL.pdf [https://perma.cc/U9NR
-RYBQ].
222. Id.
223. Jaklevic, supra note 143.
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become entangled with or transformed into reified biological
understandings of race.
To begin with, the FDA has never specified how much minority
representation it wanted to see in COVID-19 vaccine trials, and NIH
Director Francis Collins acknowledged in July 2020 that there was no
general agreement on the percentage of minorities the trials should
include. While some scientists were arguing that percentages should be
representative of the distribution of the current burden of disease,
others were arguing for more straightforward demographic
representation equivalent to each group’s percentage of the overall use
population – approximately 13% for Blacks and 18% for non-White
Hispanics.224
In August 2020 Director Fauci told CNN that he “wanted to see
minorities enrolled in coronavirus vaccine trials at levels at least double
their percentages in the population, because Covid-19 has hit those
groups especially hard.”225 That would equate to roughly 26% percent
representation for Blacks and 36% for non-White Hispanics, amounting
to 62% of the entire trial population just for those two groups. The final
numbers reported by Pfizer and Moderna were nowhere near this, but
they did approach (though fall short of) proportional demographic
representation. In December 2020, shortly after the FDA had approved
the Pfizer and Moderna vaccines, the National Medical Association
reviewed the trial enrollment data and concluded that the roughly 10%
of Blacks enrolled in each trial was “sufficient to have confidence in
health outcomes of the clinical trials.”226
What does this mean in terms of absolute numbers? In any clinical
trial, if there is a population of interest, enough of those subjects should
be enrolled to provide statistically robust data about that population.
A typical Phase 3 drug trial enrolls between 300 and 3,000 subjects.227
Phase 3 trials demonstrate whether or not a product offers a treatment
benefit to a specific population and immediately precede submission for
FDA approval.228 Vaccine trials are often much larger, usually in the
tens of thousands, in part because they are typically administered to
large numbers of otherwise healthy individuals; and so concerns for
224. Id.
225. Cohen, supra note 144.
226. NMA COVID-19 Task Force on Vaccines and Therapeutics, Advisory

Statement on Federal Drug Administration’s Emergency Use
Authorization Approval for Pfizer and Moderna Vaccine, NAT’L MED.
ASS’N (Dec. 21, 2020), https://www.nmanet.org/news/544970/NMACOVID-19-Task-Force-on-Vaccines-and-Therapeutics.htm
[https://perma.cc/FY74-8D54].
227. Step 3: Clinical Research, U.S. FOOD & DRUG ADMIN., https://
www.fda.gov/patients/drug-development-process/step-3-clinical-research
[https://perma.cc/KBE4-5TPK] (last visited Feb. 20, 2022).
228. Id.
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safety are higher.229 For example, trials for the recently developed HPV
(human papilloma virus) vaccine ranged from 5,500 to 18,500
subjects.230 One review of trials for thirteen vaccines conducted between
2000 and 2010 found that enrollment in Phase 3 trials ranged from
2,358 to 80,427 with a mean of 29,844 and a median of 22,938.231 As
noted above, Pfizer enrolled 40,477 subjects and Moderna 30,351 in
their COVID-19 trials, thus falling within a fairly standard range,
somewhat above both the mean and the median for recent vaccine
trials. While the considerations in designing a vaccine trial differ
somewhat from those of designing a drug trial, it is worth considering
that between them, in absolute numbers, Pfizer and Moderna enrolled
6,633 Black subjects.232 Indeed, it is over six times the number enrolled
in the Phase 3 trial for the race-specific heart failure Drug, BiDil, which
enrolled only self-identified African American subjects.233 In such cases
6,663 subjects would clearly be deemed “enough” representation to
address issues of safety and efficacy.
Vaccine trials typically try to enroll larger numbers. Consider the
total of 6,633 as compared with the median and mean numbers from
the study mentioned above. The 6,633 would amount to approximately
22% of the mean enrollment of 29,844 and 29% of the median enrolment
of 22,938, coming very close to the enriched representation numbers
suggested by Dr. Fauci. These are very crude calculations and not
directly applicable to the complexities of evaluating the adequacy of a
given trial design. Nonetheless, they are instructive for thinking about
how “representation” was being conceptualized in relation to COVID19 vaccine trials and just what sorts of consideration might be used in
considering how much “diversity” is enough. These figures also bring
into relief the sort of diversity panic that seemed to swirl around the
229. Paul Griffin, Explaining Vaccine Clinical Trial Phases, MED. XPRESS
(Aug. 27, 2020), https://medicalxpress.com/news/2020-08-vaccineclinical-trial-phases.html [https://perma.cc/Z7LE-QXVL].
230. John T. Schiller, Xavier Castellsagué, & Suzanne M. Garland, A Review
of Clinical Trials of Human Papillomavirus Prophylactic Vaccines,
VACCINE, 2012, at 1, 3.
231. Steven H. Weinberg, Amy T. Butchart, & Matthew M. Davis, Size of
Clinical Trials and Introductory Prices of Prophylactic Vaccine Series,
HUMAN VACCINES & IMMUNOTHER., 2012, at 1, 2.
232. Admittedly, combining numbers from two different vaccine trials is
problematic for numerous reasons. Nonetheless, the vaccines were based
on similar technologies and had similar safety and efficacy profiles.
Combining the numbers here is not meant to make a specifical biomedical
point but rather as a heuristic device for thinking about how numbers are
being conceptualized in relation to “diversity” and “representation” in
these trials.
233. See Anne L. Taylor et al., Combination of Isosorbide Dinitrate and
Hydralazine in Blacks with Heart Failure, 351 NEW ENG. J. MED. 2049,
2049-50 (2004).
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trial enrollment process -- a panic, it seems, which cannot be wholly
explained by biomedical considerations of safety, efficacy, and
generalizability. Rather, the widespread calls for diversity in clinical
trials gained much of their urgency by combining such biomedical
concerns with broader social concerns relating to trust and vaccine
hesitancy, and political concerns for equity.
A. Unpacking the Social Rationales for Diverse Vaccine Clinical Trials

Foremost among the social rationales for increasing vaccine trial
diversity was a concern to address issues of trust and vaccine hesitancy
in minority, particularly Black, communities.234 In 2015, the SAGE
Working Group on Vaccine Hesitancy defined vaccine hesitancy as,
“delay in acceptance or refusal of vaccination despite availability of
vaccination services.”235 The report also noted that it is “complex and
context specific, varying across time, place and vaccines. It is influenced
by factors such as complacency, convenience and confidence.”236 Vaccine
hesitancy, in short, is neither a static nor monolithic phenomenon. It
can range from unyielding “anti-vaxxers” who will not get any vaccine
under any circumstance to those who simply do not wish to be first in
line, but rather, want to wait and see how any given vaccine roll-out
progresses. It could also include many intermediate attitudes.237 As one
review put it, “not all mistrust is created equal.”238 Vaccine hesitancy
among African Americans is distinctively situated in a history of past
and ongoing racist encounters with biomedical institutions, and in
many cases is quite different in character and tone from vaccine
mistrust expressed by White people.239 In the context of COVID-19,
such differences have become particularly pronounced over time, as
Black rates of vaccine hesitancy have steadily declined while rates of

234. See, e.g., Artiga et al., supra note 148; Zoe Christen Jones, Fauci Urges

Black Community to Be Confident in COVID-19 Vaccine: “The Time is
Now to Put Skepticism Aside,” CBS NEWS (Dec. 8, 2020), https://
www.cbsnews.com/news/fauci-black-community-covid-19-vaccine/
[https://perma.cc/L96H-MG96]; Shadim Hussain, We Need ‘Horizontal’
Trust to Overcome Vaccine Skepticism, WIRED (Nov. 21, 2020), https://
www.wired.com/story/we-need-horizontal-trust-to-overcome-vaccineskepticism [https://perma.cc/PCS7-SBK4].
235. Noni E. MacDonald & SAGE Working Group on Vaccine Hesitancy,
Vaccine Hesitancy: Definition, Scope and Determinants, 33 VACCINE 4161,
4163 (2015).
236. Id.
237. Lauren Bunch, A Tale of Two Crises: Addressing Covid-19 Vaccine
Hesitancy as Promoting Racial Justice, 33 HEC FORUM 143, 244 (2021).
238. Id. at 147.
239. Id.
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hesitancy among White Republicans (particularly White male
Republicans) have remained consistently and stubbornly high.240
Before exploring such differences further, it is useful first to
recognize that before COVID-19 there was very little, if any, discussion
of the importance of diversifying vaccine trials to address issues of trust
among minorities. One 2020 study looking at past vaccination hesitancy
experiences in order to develop “a Social and Behavioral Research
Agenda to Facilitate COVID-19 Vaccine Uptake in the United States”
focused on the importance of improving experiences of health care
delivery and listed many strategies for improving “transparency and
community engagement,” but nowhere did it consider diversifying
vaccine trials as a means to improve trust and increase vaccine
acceptance.241 A major 2016 review of 43 studies of vaccine hesitancy
listed 23 different determinants affecting vaccine uptake; diversifying
clinical trials was not among them, nor was it even mentioned in the
article.242 Beyond this, the article concluded that “most interventions
to increase vaccine acceptance have shown little or no effect.”243 The
SAGE Working Group of Vaccine Hesitancy similarly found “that,
despite extensive literature searching, there are (1) few existing
strategies that have been explicitly designed to address vaccine
hesitancy; and (2) even fewer strategies that have quantified the impact
of the intervention.”244
In light of such findings, it is perhaps surprising that so many
biomedical professionals, academics, and policymakers assumed without
evidence that diversifying clinical trials (a strategy that had not even
been the subject of previous studies) would reduce vaccine hesitancy
240. Perry Bacon Jr., Why a Big Bloc of Americans is Wary of the COVID-19
Vaccine – Even as Experts Hope to See Widespread Immunization,
FIVETHIRTYEIGHT (Dec. 11, 2020), https://fivethirtyeight.com/features/
many-black-americans-republicans-women-arent-sure-about-taking-acovid-19-vaccine/ [https://perma.cc/HBQ8-PRW2]; Cary Funk & Alec
Tyson, Growing Share of Americans Say They Plan to Get a COVID-19
Vaccine – Or Already Have, PEW RES. CTR. (Mar. 5, 2021), https://
www.pewresearch.org/science/2021/03/05/growing-share-of-americanssay-they-plan-to-get-a-covid-19-vaccine-or-already-have/
[https://
perma.cc/VRR4-NE5E]; National: One in Five Still Shun Vaccine,
MONMOUTH UNIV. POLLING INST. (Apr. 14, 2021), https://
www.monmouth.edu/polling-institute/reports/monmouthpoll_US_
041421/ [https://perma.cc/CP99-PZUG].
241. Emily K. Brunson & Monica Schoch-Spana, A Social and Behavioral

Research Agenda to Facilitate COVID-19 Vaccine Uptake in the United
States, 18 HEALTH SECURITY 338, 340-41 (2020).
242. Angus Thomson et al., The 5As: A Practical Taxonomy for the
Determinants of Vaccine Uptake, 34 VACCINE 1018, 1018 (2016).
243. Id.
244. Caitlin Jarrett et al., Strategies for Addressing Vaccine Hesitancy – A
Systematic Review, 33 VACCINE 4180, 4186 (2015).
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among affected minority groups. As an illustrative example, consider a
2021 statement from the Kaiser Family Foundation on “Racial
Diversity within COVID-19 Vaccine Clinical Trials: Key Questions and
Answers,” which declared without citation that “[d]iversity within
clinical trials for a COVID-19 vaccine helps ensure safety and
effectiveness across populations and may increase confidence in getting
the vaccine among people of color.”245 A 2021 study published in JAMA
Network Open on diversity in clinical trials similarly asserted that
“[i]mproving racial/ethnic diversity in clinical trials is important
because enrollment may be associated with vaccination rates in
minority groups. Efforts to improve inclusion may help to address
vaccine hesitancy, provide education, and counter safety concerns about
vaccines by ensuring equitable representation in definitive clinical
trials.”246 Note the equivocal use of the term “may” to qualify these
claims. This was perhaps wise because, while the authors here did
provide three citations to support this claim, none of the cited studies
actually discussed diversifying clinical trials as a means to address
vaccine hesitancy; instead, they simply explored the phenomenon
generally in certain minority populations. 247 As Ballantyne and
Ganguli-Mitra note, “[g]reater participation of minoritized groups in
trials may lead to greater trust in the vaccine products— but not
necessarily.”248
Those wringing their hands about potential vaccine hesitancy
among minority populations might have done well to consider such
studies as the one conducted in 2014 by the CDC’s Office of Minority
Health and Health Equity. The CDC study found that the
Congressionally-authorized Vaccines for Children program had
effectively reduced racial and ethnic disparities in vaccination coverage
for the MMR and Polio vaccines by focusing on providing practical
access.249 Addressing structural issues is thus perhaps more relevant to
addressing disparities than speculating about changing trust attitudes
through diversifying clinical trials. Such a conclusion comports well
with the findings of the Tuskegee Legacy Project, which addressed a
range of issues related to the recruitment and retention of Blacks and
other minorities in biomedical research studies in the early 2000s.250 The
245. Artiga et al., supra note 148.
246. Flores et al., supra note 177, at 6 (emphasis added).
247. See id.
248. Ballantyne & Ganguli-Mitra, supra note 203, at 101.
249. Allison T. Walker et al., Reduction of Racial/Ethnic Disparities in
Vaccination Coverage, 1995-2011, 63 MORBIDITY & MORTALITY WKLY.
REP. 7, 7 (2014).
250. Ralph V. Katz et al., The Tuskegee Legacy Project: Willingness of
Minorities to Participate in Biomedical Research, 17 J. HEALTH CARE
POOR UNDERSERVED 698, 698 (2006); Ralph V. Katz et al., Willingness of
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Tuskegee Project found that “although Blacks self-report having a
higher fear of participation, they are just as likely as Whites to selfreport willingness to participate in biomedical research.” 251 In these
contexts, wariness or mistrust did not translate directly into a refusal
to participate.
There is also an important distinction to be made between vaccine
hesitancy and trial hesitancy. At an outreach session to Black
Americans conducted at Meharry Medical College in the summer of
2020, one participant declared: “The word ‘vaccination’ don’t scare
me . . . the word ‘trial’ do.”252 Similarly, there was pushback when the
presidents of the Dillard and Xavier Universities (both HBCUs) urged
community members to participate in clinical trials. “Our children are
not lab rats for drug companies. I cannot believe that Xavier is
participating in this,” wrote one parent on Xavier’s Facebook page.253
Such sentiments raise the concern that overzealous calls to diversify
clinical trials could create a backlash in terms of both trial and vaccine
hesitancy. First, as noted by Rachel Hardiman, of the Center for
Antiracism Research for Health Equity at the University of Minnesota,
over-energetic outreach to Black communities could increase wariness,
rather than alleviate it.254 Those targeted may simply, and for good
reason, feel they are being exploited – like lab rats – and hence decline
to participate. Second, if the trials themselves do not meet those
diversity goals they or others have set, then taking the proffered
biological rationales for diversity at face value, members of minority
groups might reasonably conclude that the vaccines have not been
proven safe or effective for their group. In calling for increasing diverse
enrollment in trials in a New York Times Op-Ed, leaders from several
major HBCU medical centers fed into this dynamic, asserting that
from a Follow-up Study Using the Tuskegee Legacy
Questionnaire, 99 J. NAT’L MED. ASSOC. 1052, 1052-53 (2007).
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supra note 250, at 1052-53.
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Recruiting Black Volunteers Takes Time, NPR (Sept. 11, 2020),
https://www.npr.org/sections/health-shots/2020/09/11/911885577/ascovid-19-vaccine-trials-move-at-warp-speed-recruiting-black-volunteerstakes [https://perma.cc/ZY6P-E4DQ]. See April Dembosky, No, the

Tuskegee Study is Not the Top Reason Some Black Americans Question
the COVID-19 Vaccine, KQED (Feb. 25, 2021), https://www.kqed.org/
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[https://perma.cc/YYK9EWVK].
253. Reuben C. Warren et al., Trustworthiness Before Trust – Covid-19
Vaccine Trials and the Black Community, NEW ENG. J. MED., Nov. 26,
2020, at e121(1), e121(1)-(2). See Dembosky, supra note 252.
254. Farmer, supra note 252.
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“[w]ithout significant participation in clinical trials, there will be no
proof that our patients should trust the vaccine.”255
Specific differences among types of vaccine hesitancy are evident
when comparing the attitudes of Black Americans vs White
Republicans. Throughout 2020, polls consistently showed Black
Americans expressing greater degrees of hesitancy than Whites, but
they also showed Republicans expressing more hesitancy than
Democrats.256 Polls conducted by the Pew Research Center showed the
percentage of Black Americans saying they would “definitely or
probably” get a vaccine falling from 54% in May to below 40% in
September and then climbing back to 42% in December.257 These
numbers were consistently close to 20% below those for Whites. During
this same period, the percentages for Republicans began at 65% in May,
falling well below 50% in September before climbing back to 50% in
December. These numbers were between 15-19% below those for
Democrats.258
Given such numbers, the widespread concern about vaccine
hesitancy among Blacks during this time is certainly understandable.
However, there was no comparable concern being expressed about
Republican hesitancy, and no evidence pointing to the need to enroll
more Republicans in vaccine trials in order to address concerns about
vaccine hesitancy. Why is it then that when it came to getting more
subjects for clinical trials, trust only became an issue for enrolling more
Black bodies instead of more Republican bodies? Clearly, there is no
definitive answer, but one cannot help but be concerned that the
difference lies, at least in part, in an implicit understanding or belief –
a frame – that Black bodies were biologically different from White
bodies while Republican bodies (quite understandably) were never
conceived of as being biologically different from Democratic bodies.
Partisan divides in vaccine hesitancy had been well documented for
years before the outbreak of COVID-19. Back in 2009, in response to
the outbreak of H1N1 (Swine Flu), a poll conducted by the Pew
Research Center found only 41% of Republicans said they would get
255. Frederick et al., supra note 156.
256. Cary Funk & Alec Tyson, Intent to Get a COVID-19 Vaccine Rises to
60% as Confidence in Research and Development Process Increases, PEW
RES. CTR. (Dec. 3, 2020), https://www.pewresearch.org/science/
2020/12/03/intent-to-get-a-covid-19-vaccine-rises-to-60-as-confidence-inresearch-and-development-process-increases/ [https://perma.cc/7NUGDZD9].
257. Id. See also Alec Tyson et. al., U.S. Public Now Divided Over Whether
to Get COVID-19 Vaccine, PEW RES. CTR. (Sept. 12, 2020), https://
www.pewresearch.org/science/2020/09/17/u-s-public-now-divided-overwhether-to-get-covid-19-vaccine/ [https://perma.cc/296N-T9G4].
258. Tyson et. al., U.S. Public Now Divided Over Whether to Get COVID-19
Vaccine, supra note 257.
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vaccinated, compared to 60 percent of Democrats.259 As Matt Nisbet
noted in a 2016 article on “Partisan Pandemics:” “trust in government
was ultimately the key driver of decisions to be vaccinated. In contrast
to their Democratic counterparts, Republicans . . . were less likely to
say that they were willing to take the vaccine.”260 Similarly, a 2018
study found that Republicans were far more likely than Democrats to
have inaccurate beliefs about vaccines and attributed that difference,
at least in part, to “Democrats’ greater support for government
programs and science;”261 a finding echoed in another 2018 study
concluding that political ideology had a powerful effect on attitudes
toward vaccines “that is mediated by trust in government medical
experts.”262
Awareness of the partisan divide was not confined to the pages of
academic journals. In May 2019, Politico published an article titled:
“How the anti-vaccine movement crept into the GOP mainstream.” In
the story, Stephanie Wasserman, executive director of the Colorado
Children’s Immunization Coalition, noted that “the antivax messaging
has shifted from a focus on questions of safety to things like parental
rights and data privacy, and those messages resonate more with
conservative lawmakers and play to the GOP political base.”263 The
shift in focus from safety to freedom is notable both because it presaged
much Republican resistance to COVID-19 vaccines and because it
contrasts markedly with the type of mistrust expressed by Blacks. This
shift has its recent roots in vaccine efforts undertaken by the Obama
administration in 2009 in response to the Swine Flu. As conservative
commentator Glenn Beck told his roughly 3 million followers in 2009,
“if you have some idiot government official demanding, telling me I
must take this vaccine, I’ll never take it.”264 There was invariably an
259. Growing Interest in Swine Flu, Many See Press Overstating Its
Danger, PEW RES. CTR. (Oct. 15, 2009), https://www.pewresearch.org/
politics/2009/10/15/growing-interest-in-swine-flu-many-see-pressoverstating-its-danger/ [https://perma.cc/WJP5-XC65].
260. Matt Nisbet, Partisan Pandemics, 40 SKEPTICAL INQUIRER, July-Aug.
2016, at 21, 22.
261. Mark R. Joslyn & Steven M. Sylvester, The Determinants and
Consequences of Accurate Beliefs About Childhood Vaccinations, 47 AM.
POL. RES. 628, 633 (2019).
262. Bert Baumgaertner et al., The Influence of Political Ideology and Trust
on Willingness to Vaccinate, 13 PLOS ONE 1, 8 (2018).
263. Arthur Allen, How the Anti-Vaccine Movement Crept into the GOP
Mainstream, POLITICO (May 27, 2019), https://www.politico.com/
story/2019/05/27/anti-vaccine-republican-mainstream-1344955 [https://
perma.cc/BA95-A66M].
264. Matthew A. Baum, Red State, Blue State, Flu State: Media Self-Selection
and Partisan Gaps in Swine Flu Vaccinations, 36 J. HEALTH POL. POL’Y
& L. 1021, 1022 (2011).
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aspect of racialization informing the rising perception that a
government led by a Black man was incompetent and a threat to
freedom.
The racialization of trust runs powerfully through recent responses
to vaccines. In January 2021, Lauren Bunch reflected upon current
issues in vaccine hesitancy in response to COVID-19 by discussing a
2016 study which found that, while Blacks’ mistrust was rooted in
concerns over governmental motives, White mistrust tended to focus
more on issues of competence.265 One might reframe this as Blacks’
concern being rooted in experiences of exploitation and Whites’ more
in an ideology of individualistic meritocracy. This difference perhaps
accounts for the radical divergence between Black and Republican
vaccine hesitancy as the vaccines were actually rolled out in 2021. In
December 2020, Black hesitancy was still quite high, with only 42%
saying they would “definitely or probably” get vaccinated, while the
number for Republicans was 50%.266 After this point, the numbers
began to change dramatically. By February 2021, Pew was finding that
61% of Blacks were saying they would “definitely or probably” get
vaccinated – only 8% below the number for Whites; in contrast, only
56% of Republicans said they would “definitely or probably” get
vaccinated. In two months’ time the numbers had shifted by 19% for
Blacks but only 6% for Republicans.267
In March, a series of polls conducted by Civiqs showed the following
trend from November 9, 2020 to March 28, 2021: Blacks went from 41%
saying they would not get vaccinated and 23% unsure (for a total of
64% hesitant) to 11% no and 10% unsure (for a total of 21% hesitant);
Republicans went from 41% saying they would not get vaccinated and
23% unsure (for a total of 64% hesitant) to 42% no and 11% unsure
(for a total of 53% hesitant).268 By April, a poll conducted by Monmouth
University found 43% of Republicans declaring they “likely will never
get” vaccinated, in contrast to only 20% of Blacks.269 Such trends
illustrate how vaccine hesitancy is neither statis nor monolithic, and
throws into relief differences between vaccine wariness and outright
265. Bunch, supra note 237.
266. Funk & Tyson, supra note 240.
267. Id.
268. Coronavirus: Vaccination: Registered Voters, CIVIQS, https://civiqs.com/
results/coronavirus_vaccine?annotations=true&uncertainty=true&zoom
In=true&trendline=trueendline=true [https://perma.cc/M3MK-JRQT]
(last visited Mar. 28, 2021) (reporting 49,573 responses as of Mar. 28,
2021). A Kaiser Family Foundation Tracking polls sound similar
trends. KFF
Health Tracking Poll/KFF COVID-19 Vaccine
Monitor, KAISER FAM. FOUND. (2021), https://files.kff.org/attachment/
Topline-KFF-COVID-19-Vaccine-Monitor-KFF-Health-Tracking-PollFebruary-2021.pdf [https://perma.cc/G7E9-EK79].
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refusal. Blacks’ concerns over exploitation were apparently susceptible
to amelioration through experience. For Republicans, however, antigovernment attitudes and suspicion of expertise remained relatively
intransigent. The polling trends would seem to indicate that Blacks
were taking a wait-and-see attitude toward the vaccine and have
steadily moved toward acceptance. Republicans, in contrast, have
demonstrated remarkably consistent and stubbornly high levels of
outright refusal in their stance toward vaccination.
The shift in Black attitudes could be held up as evidence of the
success in diversifying clinical trials in reducing Black hesitancy. There
is no evidence to support this conclusion. There is evidence, however,
from the studies discussed above first, previous attempts to address
vaccine hesitancy generally had little effect; and second, that Blacks,
while initially more hesitant than Whites, would get vaccinated in
similar numbers if simply given access.
Despite the well-document partisan differences in vaccine hesitancy
going back over a decade, it was not until such trends became evident
in early 2021 that biomedical professionals, commentators, and
policymakers started wringing their hands over Republican vaccine
hesitancy – this despite the fact the overall response to the pandemic
had become highly politicized and polarized over the course of 2020.270
While major initiatives were taken to address Black vaccine hesitancy
by seeking to enroll more Black bodies in vaccine trials, no one was
calling for demographically representative samples of Republicans to be
enrolled. Moderna did not pause its trial so that it could enroll more
Republicans. From all indications, partisan affiliation of those enrolling
in clinical trials was never tracked. It certainly was not presented in the
demographic breakdown of trial results to the FDA by vaccine
developers.
In other words, as COVID-19 ravaged through the United States
during 2020 and vaccine developers were frantically seeking to enroll
people in clinical trials, somehow White mistrust, specifically White
Republican mistrust, was largely ignored – that is until the clinical
trials were completed, the vaccines came online, and it became evident
that White Republican vaccine refusal presented a much greater
challenge than Black vaccine wariness.

270. See, e.g., Hunt Allcott et al., Polarization and Public Health: Partisan
Differences in Social Distancing During the Coronavirus Pandemic, 191 J.
PUB. ECON. 1, 3 (2020); see also Anton Gollwitzer et al., Partisan

Differences in Physical Distancing Are Linked to Health Outcomes During
the COVID-19 Pandemic, 4 NATURE HUM. BEHAV. 1186, 1186-91 (2020);
J. Clinton et al., Partisan Pandemic: How Partisanship and Public Health
Concerns Affect Individuals’ Social Mobility During COVID-19, 7 SCI.
ADVANCES, Jan. 6, 2021, at 1, 1-2.
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1. The Racialization of Trust

How specifically, then, did trust become racialized during the
COVID-19 pandemic and what sort of work did this racialization do?
Black mistrust of biomedical institutions is a widely recognized and
much-discussed phenomenon. It has been part of the debates around
increasing inclusion in clinical trials going back to the NIH
Revitalization Act of 1993.271 Many calls for inclusion invoked the
legacy of the Tuskegee syphilis experiments272 where, for decades,
representatives from the U.S. Department of Public Health withheld
treatments from Black men in order to study the course of a disease
that they thought functioned somehow differently in Black bodies.273
Typical of such framings is a report from National Public Radio that
opened: “A lingering mistrust of the medical system makes some Black
Americans more hesitant to sign up for COVID-19 vaccines . . . The
mistrust is rooted in history, including the infamous U.S. study of
syphilis that left Black men in Tuskegee, Ala., to suffer from the
disease.”274 Notably, this report aired in mid-February 2021, well after
polls had begun to show a dramatic shift in Black attitudes toward
vaccine acceptance, thus testifying to the power of this narrative. One
problem with framing the issue in this manner is that there is little
evidence, if any, to support it. Back in 2006, the Tuskegee Legacy
Project found that there was no association between knowledge of
Tuskegee and actual willingness to participate in research. 275 Reflecting
back on the Project during the height of the COVID-19 pandemic, Dr.
Reuben Warren, director of the National Center for Bioethics in
Research and Health Care at Tuskegee University in Alabama, declared
that the association of Tuskegee with Black vaccine refusal “was a false
assumption . . . The hesitancy is there, but the refusal is not. And
that’s an important difference.”276

271. EPSTEIN, supra note 133, at 42-44, 187-95.
272. See, e.g., Bunn, supra note 154; Dembowsky, supra note 252.
273. Allan M. Brandt, Racism and Research: The Case of the Tuskegee
Syphilis Study, 8 HASTINGS CTR. REP., 21, 21 (1978).
274. Debbie Elliott, In Tuskegee, Painful History Shadows Efforts to Vaccinate
African Americans, NAT’L PUB. RADIO (Feb. 16, 2021), https://
www.npr.org/2021/02/16/967011614/in-tuskegee-painful-historyshadows-efforts-to-vaccinate-african-americans [https://perma.cc/L8ZDZJ36].
275. Katz et al., The Tuskegee Legacy Project, supra note 250, at 707.
276. April Dembosky, Stop Blaming Tuskegee, Critics Say. It’s Not an
‘Excuse’ for Current Medical Racism, KAISER HEALTH NEWS (Mar. 25,
2021), https://khn.org/news/article/stop-blaming-tuskegee-critics-sayits-not-an-excuse-for-current-medical-racism
[https://perma.cc/4F3VTD88].
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Much more powerful in driving contemporary Black hesitancy has
been the Black community’s ongoing everyday lived experiences of
racism in encounters with the health care system. As Dr. Lauren
Nephew wrote in January 2021, “as a Black woman, I have borne
witness to the very system that says it is ready to protect me with a
vaccine, systematically disempower my community, putting many at
risk of comorbidity and death. . . . Unfortunately, this lack of trust is
not just the result of residual pain from past atrocities like the Tuskegee
experiments . . . Many patients of color, including myself, can describe
present-day experiences in the health care system where we have been
discounted, ignored, and devalued.”277 Dr. Nephew also cited the case
of Dr. Susan Moore, a black physician, whose video of experiencing
racism while being treated for COVID-19 went viral after she died from
the disease. 278 “‘He made me feel like a drug addict,’ Dr. Susan Moore
said, accusing a white doctor of downplaying her complaints of pain
and suggesting she should be discharged.”279 As the New York Times
noted, “Dr. Moore’s experience highlighted what many Black
professionals said they regularly encountered. Education cannot protect
them from mistreatment, they say, whether in a hospital or other
settings.” 280
The focus on Black trust did the work of diverting attention away
from the structural and institutional underpinnings of COVID-19 racial
disparities and allowed society to concentrate instead on the subjective
attitudes of Black people. Focusing on the symptom of vaccine
hesitancy allowed policymakers and biomedical professionals to avoid
addressing the underlying structural causes of the mistrust. “It’s a
scapegoat,” said Karen Lincoln, a professor of Social Work at the
University of Southern California. “It’s an excuse. If you continue to
use it as a way of explaining why many African Americans are hesitant,
it almost absolves you of having to learn more, do more, involve other
people – admit that racism is actually a thing today.”281 As historian of
Tuskegee, Susan Reverby, put it: “the news media’s focus on mistrust
or seemingly ridiculous conspiracies . . . ignores the racist structures
that shape economic, political, and social realities that lead to health
disparities. The alarming statistics on who is getting the vaccines, and
who is not, should shift our attention away from mere mistrust in
277. Lauren D. Nephew, Systemic Racism and Overcoming My COVID-19
Vaccine Hesitancy, ECLINICAL MED., Feb. 1, 2021, at 100713.
278. Id.
279. John Eligon, Black Doctor Dies of Covid-19 After Complaining of Racist
Treatment, N.Y. TIMES (Dec. 23, 2020), https://www.nytimes.com/2020/
12/23/us/susan-moore-black-doctor-indiana.html
[https://perma.cc/
L59Y-94XC].
280. Id.
281. Dembosky, supra note 252.
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communities of color and toward the structures of racism that cause
that mistrust.”282
During 2020, a focus on Black mistrust became a cheap and easy
way to superficially address concerns about the manifest problem of
racial disparities. This focus may explain why White Republican
mistrust was of no major concern until 2021. White Republicans were
not experiencing a disproportionate burden of COVID-19 morbidity and
mortality, so there was no need to divert attention from any deeper
structural issues giving rise to the mistrust. White mistrust was not
perceived to be a problem until 2021 because it was not related to issues
of racial equity but rather to concerns about herd immunity. This
problem did not become manifest until 2021, and so it was not until
then that White mistrust became a concern among policymakers and
the broader public health community.
B. Unpacking the Political Rationales for Diverse Vaccine Clinical Trials

Concerns for racial equity lie at the heart of the political rationales
for diversifying COVID-19 vaccine trials. In her August 2020 letter to
Director Collins and Director Fauci, Representative Nanette Diaz
Barragán (D-Calif) directly connected her call to diversify trials to
equitable “access to the full range of treatments” for COVID-19.283 A
similar letter sent by 22 members of Congress to FDA Commissioner
Stephen Hahn and Secretary of Health and Human Services Alex Azar
in June 2020 emphasized that diverse clinical trials were essential “to
ensure that no demographic group is left behind.”284 The working
assumption was that diverse representation in trials was a prerequisite
to racially equitable access to safe and effective treatments.
1. Bearing the Burdens of Diversity

In this scheme, what are the burdens of diversity and who bears
them? The dangers of COVID-19 are linked to concepts of risk – risk
of contracting the virus, risk of morbidity and mortality from
contracting the virus, and risk of “being left behind” or not having
282. Susan M. Reverby, Racism, Disease, and Vaccine Refusal: People of Color
Are Dying for Access to COVID-19 Vaccines, 19 PLOS BIOL. e3001167
(2021).
283. Letter from Rep. Nanette Diaz Barragán to Francis Collins, Director,
Nat’l Inst. of Health and Anthony S. Fauci, Director, Nat’ Inst. of Allergy
and Infectious Disease (Aug. 25, 2020), https://barragan.house.gov/wpcontent/uploads/2020/08/Vaccine-Trial-Locations-Barragan.pdf
[https://perma.cc/PL8Q-F5VR].
284. Letter from Rep. Sean Casten et al. to Stephen Hahn, Comm’r, Food &
Drug Admin. and Alex M. Azar II, Sec’y, Dep’t of Hum. Health Services
(June 16, 2020), https://luria.house.gov/sites/luria.house.gov/files/
wysiwyg_uploaded/6.16.20_Letter%20to%20Commissioner%20Hahn%20
and%20Secretary%20Azar%20on%20COVID-19%20Vaccine%
20Inclusion.pdf [https://perma.cc/4VKU-A64M].
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access to vaccines and other care. As Paul Slovic has argued, “danger
is real, but risk is socially constructed . . . Whoever controls the
definition of risk controls the rational solution to the problem at
hand.”285 In 2020 there was a recognized and very real danger that
COVID-19 was having a disproportionate impact on racial minorities.
In addressing this danger, calls to diversity clinical trials defined risk in
terms of representation of Black and Brown bodies. If there was not a
sufficiently diverse representation of subjects in vaccine trials then we
risked the possibility that the vaccines might not be safe and effective
for all groups, thereby exacerbating disparities. Thus, researchers had
to make concerted efforts to reach out to communities of color and
convince them to enroll. Even if a given vaccine were proven safe and
effective in all groups, there was the additional risk that communities
of color, particularly Black Americans, might be mistrustful and
hesitate to get vaccinated. Diversifying clinical trials was also cast as a
means to address this risk.
These constructions of risk place the burdens of addressing
disparities directly on the minds and bodies of Black people. Instead of
focusing on the need to develop a better community health
infrastructure to ensure equitable access to vaccines and related health
care, the focus on diversifying clinical trials foregrounded access as a
function of the willingness of Black people to make their bodies
available for medical experimentation – which, after all is what a “trial”
is. Highlighting trust as a barrier to vaccine uptake makes the problem
of potential disparities in vaccine uptake a function of addressing
attitudes in Black minds. In this framing, the problem is not the
ongoing practices and structures of racism; rather, it is the attitudes of
Black people. What needs to be changed here is Black minds, not White
institutions. Moreover, emphasizing the legacy of Tuskegee makes it
seem like the racism responsible for fostering such mistrust is largely a
thing of the past, marginalizing the significance of ongoing lived
experiences of racism in the health care system.
Similarly, calling for diversity also in the biomedical workforce in
order help encourage minority enrollment or mitigate disparities
similarly places the burdens on those “diverse” hires.286 The implication
of such calls is that the mere act of hiring Black and Brown
professionals will address the problem of trust in the community.
Beyond perhaps taking a course in “cultural competency,” (which has
been happening at medical schools and medical centers for years),
White professionals do not have to confront their own racist behavior,
change their practices, or redistribute resources. All they have to do is
diversify the workforce a bit and the rest will take care of itself. Or

285. Paul Slovic, Trust, Emotion, Sex, Politics, and Science: Surveying the
Risk Assessment Battlefield, 19 RISK ANALYSIS 689, 689 (1999).
286. See, e.g., Saini et al., supra note 72; Frederick et al., supra note 151.
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rather, the newly hired “diverse” professionals will take care of
diversifying enrollment for them.
Given that the studies finding that most interventions to address
vaccine hesitancy had little or no effect, why did so many policymakers
and biomedical professionals think that increasing diversity of
enrollment was necessary?287 The answer may be that it was easier to
focus on changing Black minds than to improve the infrastructure of
vaccine delivery. If diverting attention from larger, more difficult
structural reforms involved getting more bodies enrolled in clinical trials
– so much the better.
I do not mean to assert that there was some sort of nefarious
conspiracy to exploit Black bodies and divert attention from deeper
structural issues. I do not think calls to diversify clinical trials
necessarily involved the sort of “predatory inclusion” identified by
Keeanga-Yamahtta Taylor in her study of real estate practices and
mortgage pricing in the African American community.288 Nonetheless,
the fact remains that the rationales for including more Black bodies in
the COVID-19 vaccine trials were tenuous; further, they dangerously
threatened to reify race as genetic, thereby potentially inadvertently
worsening problems of racial disparities they were trying to address.
Calls for inclusion are appealing because they are comparatively easy.
Such calls do not involve conflict or competition for limited resources.
They merely expand the pie –and in this case, the pie is simply the
number of available test subjects.
In this framing, inclusion becomes a substitute for substantive
equity. Without evidence, this frame assumes that downstream
inclusion will reduce vaccine hesitancy and improve disparities.
Increasing enrollment, in whatever form, serves the interests of those
conducting the research – i.e., pharmaceutical corporations. Focusing
on equity in trial enrollment diverts attention not only from structural
conditions causing disparities, it also diverts attention away from
economic issues specific to vaccine equity, such as intellectual property
protection.289
The intellectual property issue had been raised as early as April
2020, when a group of intellectual property scholars came together to
propose an “Open COVID Pledge” in response to President Trump’s
287. Thomson et al., supra note 242.
288. KEEANGA-YAMAHTTA TAYLOR, RACE FOR PROFIT: HOW BANKS AND THE
REAL ESTATE INDUSTRY UNDERMINED BLACK HOMEOWNERSHIP 5 (2019).
289. See, e.g., Sheryl Gay Stolberg et al., Pressure Mounts to Lift Patent
Protections on Coronavirus Vaccines, N.Y. TIMES (May 3, 2021),
https://www.nytimes.com/2021/05/03/us/politics/biden-coronavirusvaccine-patents.html [https://perma.cc/PW62-LQJK]; Walden Bello,
The West Has Been Hoarding More Than Vaccines, N.Y. TIMES (May 3,
2021), https://www.nytimes.com/2021/05/03/opinion/covid-biden-wtovaccine.html [https://perma.cc/PEV6-9886].
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emergency orders on COVID-19.290 “The Open COVID Pledge call[ed]
upon organizations around the world to make their patents and
copyrights freely available in the fight against the pandemic.”291 In
October 2020, India and South Africa petitioned the World Trade
Organization to waive temporarily certain intellectual property
protections to increase production of and access to vaccines.292 A year
after the initial Open COVID Pledge was proposed in April 2021, a
group of Democratic Senators sent a letter to pharmaceutical executives
calling upon them to consider loosening up access to their vaccinerelated intellectual property holdings.293 By this time, Pfizer was
reporting that it had already taken in $3.5 billion in vaccine revenues
just in the first quarter of 2021.294 Shortly after the Pfizer
announcement, the Biden administration proclaimed its support for the
WTO proposal that had been submitted by India and South Africa to
make it easier for countries that permit compulsory licensing to allow
a manufacturer to export vaccines.295 While this step was certainly
important, the call to waive patents rights, at least in the short term,
was likely more symbolic than substantive; it would still likely take
months of international negotiation before the proposal would take
effect, if at all.296 As journalist Melody Schreiber noted soon after the
290. About Us, OPEN COVID PLEDGE, https://opencovidpledge.org/about/
[https://perma.cc/VJ9A-3JAL] (last visited Feb. 6, 2022).
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https://www.nytimes.com/2021/05/04/business/pfizer-covid-vaccineprofits.html [https://perma.cc/EZP5-RK6A].
295. Ed Silverman, U.S. Will Back Proposal to Waive Intellectual Property
Rights and Boost Covid-19 Vaccine Production, STAT (May 5, 2021),
https://www.statnews.com/pharmalot/2021/05/05/biden-covid19vaccine-patent-rights/ [https://perma.cc/CX24-34JE]; Thomas Kaplan et
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Biden Administration announcement, “freeing vaccine patents is just
the first step. Next, companies need to share how to make the
vaccines—known as technology transfer—and governments need to
provide the resources, from raw materials to production capacity, to
ramp up global vaccine production in a matter of weeks instead of
years.”297 Time matters in a pandemic; it also matters in market share.
Given the choice, what corporation would not rather have had Senators
sending them letters about diversifying clinical trials instead of letters
calling upon then to vitiate their patent protection?

CONCLUSION
Two years before Derrick Bell wrote his critique of diversity as
deployed by the Supreme Court in Grutter v. Bollinger in 2003, Charles
Lawrence III expressed similar concerns over what he characterized as
“the liberal defense of affirmative action.”298 Lawrence declared himself
to be an “unambivalent advocate for affirmative action,” 299 but he, like
Bell, was profoundly uneasy at the ways in which “liberal supporters of
affirmative action have used the diversity argument to defend
affirmative action at elite universities and law schools without
questioning the ways that traditional admissions criteria continue to
perpetuate race and class privilege.” 300 I share a similar unease with
respect to the racialized response to COVID-19. On the one hand, I am
an unambivalent advocate of the need to take race-conscious measures
to address the deep, persistent, and pervasive health disparities in this
country. On the other hand, I am intensely wary of attempts to do so
in ways that either biologize race or divert attention from deeper
structural issues of racism – or both. The otherwise well-meaning liberal
concern to take race seriously in the face of a global pandemic is
laudable, but like the liberal approach to affirmative action, it might
win certain discrete battles (as it did in Grutter v. Bollinger) while
losing the larger war of challenging race-based privilege.
In the case of COVID-19, I am concerned that some of the wellmeaning short-term means chosen to address racial disparities might
end up placing the end of racial health justice further out of reach. In
2001, Charles Lawrence III argued that “as diversity has emerged as
on-covid-19-vaccines-in-near-term-may-be-more-symbolic-thansubstantive/ [https://perma.cc/5LBB-4NT].
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the dominant defense of affirmative action in the university setting, it
has pushed other, more radical substantive defenses to the background.
These more radical arguments focus on the need to remedy past
discrimination, address present discriminatory practices, and reexamine
traditional notions of merit and the role of universities in the
reproduction of elites.” 301 In the story of liberal responses to COVID19, the general desire to address issues of racial justice was certainly
justified. But, proximate concerns about the safety, efficacy, and uptake
of vaccines across racial groups were largely based on weak empirical
data and faulty assumptions about biological difference and the sources
of Black mistrust. As a result, the means taken to address those
concerns, while functioning to signal a symbolic concern for racial
equity, may actually have been reinforcing pernicious ideas about
essential biological difference among the race while “push[ing] other,
more radical substantive” approaches to addressing the structural bases
of health disparities “to the background.”302 This tends to be how the
discourse of diversity works, whether in affirmative action or in health
disparities. In the case of health disparities, this discourse has the added
danger of confusing and conflating socio-political concepts of diversity
with genetic concepts of diversity. Even in the face of the victory for
affirmative action in Grutter v. Bollinger, Bell lamented: “These are
difficult times for those working for racial equity, and there seemed
reason for declaring victory after a years-long litigation that many,
including this writer, predicted would result in the invalidation of any
use of race in the admissions process. I fear, though, that further eventseven in the short term- will render this latest civil rights victory, like
so many before it, hard to distinguish from defeat.”303
There are no easy solutions to the issues I have identified in this
article. Over the years many suggestions have been presented to guide
the responsible use of racial categories in biomedicine, yet these
problems persist.304 Given the complex and dynamic nature of how race
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is understood and deployed in biomedical contexts and the persistent
controversies around recognizing and addressing the historical and
structural manifestations of racism in health and healthcare, I am
hesitant to proffer any definitive actions that must be taken to avoid
the dangers of geneticizing both race and racial disparities. The most
important thing, perhaps, is simply to remain attentive to the dynamics
I have discussed here and demand that those who are using racial
categories provide more complete and clearer justifications for how they
are choosing to use race in particular situations. This is even more
important under emergent exigent circumstances such as a pandemic.
Bearing this in mind, I offer the following modest suggestions for
researchers, clinicians, and policymakers to consider:
1. Adopt a skeptical attitude toward any hypothesized but not
yet proven causal link between genetics and disparities. Note that this
is different from looking at genetic contributions to specific conditions,
for example, high blood pressure (or COVID-19), that
disproportionately impact minoritized communities. Understanding
genetic contributions to disease is quite distinct from understanding
genetic contributions to disease disparities. Do not confuse or conflate
the two.
2. When social, historical, legal, and economic factors are clearly
shown to be significant contributors to an observed disparity, adopt a
null hypothesis approach assuming that such disparities are NOT
driven by genetics until proven otherwise.
3. When seeking to diversify clinical trials, particularly under
emergent circumstances, clearly distinguish between social or political
reasons for inclusion - such as encouraging trust or increasing equitable
access to therapies - versus biological or genetic reasons, such as
concerns about generalizability or genetically based differential
responses to safety or efficacy.
4. When seeking to diversify trials to address such social concerns
as trust or vaccines hesitancy, do not simply assume that diversity in
trials will address the problem. Do not use this as a rationale to address
issues of trust or hesitancy unless you have evidence to support it.
5. When seeking to diversify trials to address biological concerns,
especially with vaccines, again assume a null hypothesis: do not assume
racial or ethnic diversity is necessary to ensure cross racial/ethnic safety
and efficacy unless you have sound evidence supporting the assumption.
The mere fact that some drugs have on average shown differential rates
of efficacy across racial groups on their own is not enough, as drug
response can be affected by myriad social and environmental factors.
With respect to vaccines, the fact that certain alleles appear to occur
at different frequencies in different populations is not enough to justify
calls for racial diversity unless you can show that those alleles have a
Yudell et al., NIH Must Confront the Use of Race in Science, 396
SCIENCE 1313, 1313 (2020).
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direct relation to vaccine response and that the difference in frequencies
is significant enough in absolute terms to merit substantial race-based
diversification in the trial population. If you are using racial categories
as proxies for certain environmental or social factors that might affect
vaccine response, be explicit about this, and maintain clarity about the
use of race as a proxy throughout the process.
6. Do not assume that the mere substitution of terms such as
“genetic ancestry” for race will solve any of these problems. In practice,
genetic ancestry all too readily becomes continental ancestry which, in
turn, blurs back into racial classifications. If you use terms such as
“genetic ancestry,” be specific about precisely what you mean by this
term and how it is being used to construct groupings among presentday populations.
Reflecting back upon the first year of COVID-19, we can see that
in the short term, vaccine developers did a decent job of enrolling
minorities in their clinical trials. In the short term, all of the vaccines
have proven to have the same safety and efficacy across races. And in
the short term, Black hesitancy has not proved to be a significant
obstacle to vaccination. This is all to the good; but let us be careful as
we move forward to ensure that the stories we tell of these short-term
successes do not further contribute to the narrative that the best way
to promote health equity is to focus on purported genetic differences in
Black bodies or allegedly misguided attitudes in Black minds. Let us
not reflect back upon these victories and find them hard to distinguish
from defeat.
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